
The publisher’s version can be accessed at:

- [https://dx.doi.org/10.1074/jbc.RA118.005723](https://dx.doi.org/10.1074/jbc.RA118.005723)

The output can be accessed at: [https://repository.rothamsted.ac.uk/item/8w908](https://repository.rothamsted.ac.uk/item/8w908).

© 17 January 2019, AUTHORS
Oleuropein derivatives from olive fruit extracts reduce α-synuclein fibrillation and oligomer toxicity

Hossein Mohammad-Beigi 1*, Farhang Aliakbari 1,2, Cagla Sahin 1,2, Charlotte Lomax 4, Ahmed Tawfikey 4, Nicholas P. Schafer 10, Alireza Amiri-Nowdijeh 5, Hoda Eskandari 1, Ian Max Møller 3, Mehdi Hosseni-Mazinani 5, Gunna Christiansen 6, Jane L. Ward 4, Dina Morshedi 2*, Daniel E. Otzen 1,7,8

From the 1 Interdisciplinary Nanoscience Centre (iNANO), Aarhus University, Gustav Wieds Vej 14, DK-8000 Aarhus C, Denmark 2 Department of Industrial and Environmental Biotechnology, National Institute of Genetic Engineering and Biotechnology, P.O. Box: 1417863171, Tehran, Iran 3 Department of Molecular Biology and Genetics, Aarhus University, Forsøgsvej 1, DK-4200 Slagelse, Denmark 4 Computational and Analytical Sciences Department, Rothamsted Research, West Common, Harpenden, Herts, AL5 2JQ, UK 5 Department of Agricultural Biotechnology, National Institute of Genetic Engineering and Biotechnology, P.O. Box: 1417863171, Tehran, Iran 6 Department of Biomedicine-Medical Microbiology and Immunology, Aarhus University, 8000 Aarhus C, Denmark 7 Department of Molecular Biology and Genetics, Aarhus University, Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark

Running title: Oleuropein derivatives reduce αSN fibrillation and toxicity

# Present address: N.P. Schafer, Department of Chemistry, Center for Theoretical Biological Physics, Rice University, Houston, TX 77005, USA.

*Corresponding authors: (D.E.Otzen) Tel.: +45-20725238; dao@inano.au.dk; (D.Morshedi) morshedi@nigeb.ac.ir; (H. Mohammad-Beigi) beigi@inano.au.dk

Keywords: α-synuclein; amyloid; cell toxicity; Mediterranean diet; membrane permeabilization; neurodegeneration; oligomerization; olive polyphenols; Parkinson’s disease; phenolics;

ABSTRACT

Aggregation of α-synuclein (αSN) is implicated in neuronal degeneration in Parkinson’s disease and has prompted searches for natural compounds inhibiting αSN aggregation and reducing its tendency to form toxic oligomers. Oil from the olive tree (Olea europaea L.) represents the main source of fat in the Mediterranean diet and contains variable levels of phenolic compounds, many structurally related to the compound oleuropein. Here, using αSN aggregation, fibrillation, size-exclusion chromatography–multi-angle light scattering (SEC-MALS)-based assays, and toxicity assays, we systematically screened the fruit extracts of 15 different olive varieties to identify compounds that can inhibit αSN aggregation and oligomer toxicity and also have antioxidant activity. Polyphenol composition differed markedly among varieties. The variety with the most effective antioxidant and -aggregation activities, Koroneiki, combined strong inhibition of αSN fibril nucleation and elongation with strong disaggregation activity on preformed fibrils and prevented the formation of toxic αSN oligomers. Fractionation of the Koroneiki extract identified oleuropein aglycone, hydroxy oleuropein aglycone, and oleuropein as key compounds responsible for the differences in inhibition across the extracts. These phenolic compounds inhibited αSN amyloidogenesis by directing αSN monomers into small αSN oligomers with lower toxicity, thereby suppressing the subsequent fibril growth phase. Our results highlight the molecular consequences of differences in the level of effective phenolic compounds in different olive varieties, insights that have implications for long-term human health.

Parkinson’s Disease (PD), the second most common neurodegenerative disease, is characterized by the degeneration of dopaminergic neurons in the substantia nigra pars compacta due to deposition of intracellular inclusions known as Lewy Bodies (LBs). These deposits can spread from cell to cell in a prion-
like fashion (1–4), leading to rigid posture, uncertain pace, and resting tremor. The major component of LBs is the 140-residue protein α-synuclein (αSN) which consists of three main regions: an amphiphilic N-terminal part, a non-amyloid hydrophobic β-peptide component (NAC), and an acidic C-terminus. The NAC region makes up the fibril core of amyloid fibril (5). Although monomeric αSN is intrinsically disordered (5, 6), it readily aggregates to oligomers, protofilaments, and fibrils (7, 8). αSN aggregation is extremely complex and depends on many different pathways and factors (9). The most toxic species, oligomers accumulate in the early stages of the fibril formation process and are thought to cause membrane destabilization (10), cytoskeletal changes (11, 12), mitochondrial dysfunction (11, 13, 14), and enhanced oxidative stress (11, 12, 15).

There has been an intense hunt for molecules which prevent αSN fibrillation and oligomerization and/or reduce the toxicity of preformed aggregated species. Inhibiting the interaction of oligomers with membranes, decreasing the production of reactive oxygen species (ROS) (16) and/or curbing rising cytoplasmic Ca²⁺ levels are very challenging.

The olive tree (Olea europaea) is major source of fat in the Mediterranean diet (MeDi) (17), characterized by high plant food content. The MeDi is rich in antioxidants found in olive or other plant foods which may help lower oxidative stress in brain aging by affecting the expression of genes related to oxidative stress and markers of lipid oxidation (18) as well as protecting cells against oxidative damage (19). Olive phenolic compounds protect against a number of chronic degenerative conditions and are also implicated in the antioxidant, analgesic, anti-inflammatory, antitumor, antiviral properties of the olive (20, 21). They also inhibit self-assembly of Aβ42, tau and αSN (22–24) into amyloids and toxic aggregates, possibly by preventing π–π and/or hydrophobic interactions (25, 26) and by redirecting these proteins into alternative nontoxic aggregates. Palazzi et al showed that oleuropein aglycone keeps αSN unfolded, rescues cells from oligomer toxicity, probes disaggregation of αSN aggregation, and prevents αSN binding to membranes (27). It has also been shown that olive biophenols could reduce the enzyme-induced toxicity associated with the oxidative stress involved in the progression of Alzheimer’s disease (AD) (28). Among these compounds, some such as phenolic acids and flavonoids are found in many fruits. However, the secoiriods are present exclusively in plants belonging to the family of Oleaceae which includes Olea europaea L. (29). Secoiriods include oleuropein (responsible for the bitter taste of olive fruits) and structurally related glucosides. The content of the polyphenols of olive fruit depends on the olive cultivar and the fruit ripening stage (30, 31). There are hundreds of olive varieties, classified based on their origin. Selection and promotion of beneficial polyphenol-rich olive varieties for long-term use may help combat PD at the population level.

While we do not claim that overall effects of a Mediterranean diet can be reproduced in their entirety by one or a few specific compounds, it is of basic interest to compare different olive varieties and establish causal relationships explaining their different effects. Comparison of complex mixtures such as different olive varieties under the controlled conditions has the potential to provide simple and straightforward information about the most important contributors to anti-aggregative and thus potentially anti-PD effects. Accordingly, we systematically screened extracts from different olive varieties for their ability to inhibit αSN fibrillation and formation of toxic aggregates. The assays monitored (a) kinetics, extent and end products of αSN fibrillation; (b) formation of toxic oligomers, disaggregation of preformed fibrils, induced changes in αSN through interaction with anionic vesicles and vesicle permeabilization induced by oligomers in the presence and absence of the extracts, and (c) toxicity of both extracts and αSN aggregates formed in the presence of extracts. The assays identified the extract, that most efficiently inhibited αSN fibrillation. The best extract in inhibiting αSN fibrillation was fractionated and the compounds present in these fractions were identified by LC-MS analysis.

**Results**

**Selection of Olive Fruits and Preparation of the Extracts**
Methanolic extracts were obtained from fruits of different olive varieties (Table S1). Of these, the Mediterranean varieties Koroneiki, Arbequina, and Picual are the world’s most prestigious varieties for super high density cultivation systems with excellent oil quality characteristics. (32). Zard, Mari, and Rowghani are three prevailing varieties in Iran primarily used in olive oil production. The third group consisted of nine Iranian Tarom olive varieties (T10, T15, T16, T17, T18, T20, T22, T23 and T24).

Screening against αSN Aggregation Based on ThT Screening Assays

We first screened extracts for their ability to inhibit αSN aggregation using different ThT-based plate reader assays. αSN aggregation in PBS buffer was accelerated by shaking in the presence of glass beads (31).

In the fibrillation assay, all 15 extracts showed an aggregation-inhibitory effect at 0.025 and 0.3 mg/mL by reducing the end-point ThT fluorescence level, though to different extents. At 0.3 mg/mL, 7 of the 15 extracts (T10, T17, T20, T23, T24, Rowghani, and Koroneiki, in blue in Supplementary Fig. S1A and B) reduced end-point ThT levels to 1-15 % of the control in the absence of extracts. The following experiments described in this paper focus only on these most effective 7 extracts. Dose-response curves were then recorded (Fig. 1A) and the normalized maximum ThT intensity (Fig. 1B) was used to obtain IC_{50} values (Eq.1) of the 7 top-ranked extracts (Fig. 1C). Here, the Koroneiki extract emerged as the best inhibitor. The Finke-Watzky model (Eq. 2) was fitted to the ThT kinetic data (kinetic data are summarized in Fig. 1D-F) to obtain two central parameters, namely t_{1/2} (the time required to produce half the total product) and ν (the rate of growth at t_{1/2}), from which the lag or nucleation time t_N could be calculated. The extracts reduced the level of fibrillation to different extents. All extracts except T24 produced a concentration-dependent reduction of ν and increase of t_{1/2} compared to control.

Far-UV circular dichroism spectroscopy (CD), SDS-PAGE, and TEM images validated ThT data by providing independent measurements of the extent of fibrillation and the structure of the final aggregates. Remarkably, several of the extracts maintained αSN in a largely unfolded conformation (Fig. 2A-C), particularly at 0.3 mg/mL extract. The normalized β-sheet content (%) of αSN is shown in Fig. 2D. The Koroneiki extract was particularly effective at retaining the unfolded conformation of αSN, and its preeminence compared to the other extracts became more obvious as the extract concentration was reduced to 0.15 and 0.1 mg/mL. T17, T20, T23, and T24 were least efficient in this regard, in good agreement with the ranking from the fibrillation assay.

SDS-PAGE was used to analyze the amount of soluble αSN in the supernatant after centrifugation. The 7 extracts significantly increased the amount of monomer left in the solution after 24 h incubation (Fig. 2E and Fig. S2). Low, but detectable amounts of dimers and larger aggregates are also visible in the presence of some of the extracts. For additional confirmation, the supernatants of the incubated samples of αSN in the absence and presence of 0.3 mg/ml of Koroneiki were run on a gel filtration column. As shown in Fig. 2F, Koroneiki significantly increased the amount of monomer left in the solution after 24 h incubation. Two populations of oligomers were also detectable after gel filtration of samples with Koroneiki.

The effect of 0.3 mg/ml extract on the morphology of endpoint αSN aggregates was analyzed by TEM (Fig. 2G and associated table). While the limited quantitative output from these TEM analyses preclude detailed comparison with ThT parameters such as lag time and growth rates, there is good qualitative agreement: Koroneiki and Rowghani extract completely suppress fibril formation and only oligomers are detectable, just as they very efficiently suppress ThT signals. The other extracts reduce fibril formation to a somewhat smaller extent, but still lead to significant reductions compared to the control, consistent with their overall reduction of ThT signal.

Olive Fruit Extracts Induce Formation of Different Oligomers

To study the effect of the extracts on the formation of soluble aggregates, we prepared oligomeric species of αSN in the presence and
absence of 0.15 mg/ml extracts. While fibrillation of αSN is a slow process with lag times of 10-20 h depending on protein concentration (33), oligomer formation occurs over a few (<5) hours. We have previously shown that during the oligomerization (900 rpm, 37 °C), αSN forms two populations of oligomers, largely elongated oligomers and small spherical oligomers, which increase slowly over time (7, 34). The small oligomers, estimated to contain ~ 30 monomers, form a compact prolate ellipsoid core with a number of flexible chains protruding from the surface into the solution, while the larger oligomers are concateners of the smaller ones (34).

We used SEC-MALS (Fig. 3A for Koroneiki and Fig. S3 for the others), a technique in which species are separated according to hydrodynamic radius on a SEC column, after which the concentration of the species are obtained from the peak area under the MALS peaks. We did not estimate oligomer concentration based on absorption at 280 or 215 nm since extract binding to the oligomers could affect absorption. Instead we used MALS data to allow more direct comparison of oligomer yields. This ranked the amount of large oligomers formed in the presence of the extracts in the following order: T23 > Rowghani > T10 > T24 > Koroneiki > T20, which differed significantly from that of the small oligomers (Koroneiki > T10 > T23 > Rowghani > T10 > T17 > T 24). In all cases, the level of monomers was relatively unchanged, indicating that most αSN remained unaggregated.

Olive Fruit Extracts Disaggregate Preformed Fibrils

We next used gel filtration to address whether overnight incubation with extracts could disaggregate existing αSN fibrils. We monitored this process by absorption at 215 nm, since we were mainly concerned with the appearance of soluble αSN. Addition of olive extracts led to an increase in the monomer peak, as well as the formation of soluble oligomers (eluting at 5-10 ml), particularly in the presence of 0.15 mg/mL of Koroneiki extract (Fig. 3B). Additional peaks eluting after the αSN monomer peak are C-terminal fragments of αSN formed by chemical cleavage after long-term incubation (C. Sahin et al., unpublished results). Thus existing fibrils could be disaggregated by Koroneiki extract at concentrations which also completely inhibited aggregation. The other extracts had less dramatic effects (Fig. S4), though T17 and T20 extracts in particular increased the monomer population to some extent.

Olive Fruit Extracts Inhibit Fibril Elongation

To determine whether or not the extracts could affect elongation of existing fibrils, short fibrillar seeds (5%) were added to monomeric αSN. This bypasses the nucleation step and allows us to study the elongation of existing fibrils. Koroneiki extract was the most effective inhibitor in both shaking and non-shaking assays, leading to a very extended lag phase of fibrillation (~10 h) under shaking conditions and completely suppressing fibril growth over a 45 h observation period in the absence of shaking (Fig. 3C and D). The other extracts reduced elongation rates to different extents. T23 extract performed most poorly in both assays, while T17, T10, and T20 extracts performed quiet well though not as well as Koroneiki extract. Thus, Koroneiki extract was the best inhibitor of both nucleation and fibril elongation.

Olive Fruit Extracts Do Not Inhibit the Change in αSN Structure induced by Vesicles

Interaction with anionic phospholipid vesicles induces a major increase in α-helical structure in αSN (35) (Fig. 3E). Compounds such as squalamine can displace αSN from lipid membranes and decrease the α-helical content of αSN (36). However, even at the high concentration of 0.15 mg/ml, none of the extracts prevented monomeric αSN from forming an α-helical structure in the presence of anionic vesicles of DMPG (Fig. 3F). Consistent with this, the Koroneiki extract failed to show any effect at other concentrations (0.025-0.3 mg/ml, data not shown).

Olive Fruit Extracts Are Nontoxic, Show Antioxidant Activity, and Decrease the Level of ROS in OLN-93 Cells

We evaluated the antioxidant activity of the olive extracts at 0.02-0.12 mg/mL using the DPPH• assay. All extracts showed similar dose-response levels in this assay (Fig. S5A). Further, none of the extracts showed significant toxicity
on their own towards OLN-93 and SH-SY5Y cells according to the MTT assay (Fig. S5B and Fig. S5E).

We used DCFH-DA to evaluate extract effects on ROS production in OLN-93 cells. All extracts except T24 decreased free radical formation (Fig. S5C). Further, all extracts neutralized the deleterious effect of 100 µM H2O2 (Fig. S5D) to the same concentration-independent extent.

**Olive Fruit Extracts Induce Formation of Less Toxic Aggregates and Reduce the Cytotoxicity of Oligomers to the SH-SY5Y Cells**

We evaluated the membrane permeabilization and cytotoxicity of aggregates formed during different stages of αSN fibrillation with and without extracts (Fig. 4A). Without extracts, the ability of aggregates to release calcine decreased as the aggregates aged over 24 h (Fig. 4B); several of the extracts, particularly Koroneiki, accelerated this decline. This suggests that aggregates formed in the presence of the extracts interact less with the membranes.

In the MTT cell viability assay with OLN-93 and SH-SY5Y cells, aggregates formed in the presence of the extracts showed less cytotoxicity than the extract-free αSN control samples (Fig. 4C and 4D). The aggregates were more toxic to OLN-93 cells (Fig. 4C) than to SH-SY5Y cells (Fig. 4D). While all extracts significantly enhanced viability of OLN-93 cells at the early stages (4, 8, and 12h), at 24 h this effect is just significant for T17, Rowghani, and Koroneiki extracts. However, for SH-SY5Y cells, this enhancement effect is retained for all extracts and all incubation times (Fig. 4D). A difference in response by different cell lines is not without precedent; we have also recently reported that SH-SY5Y and PC-12 cells (another neuronal cell line) differ in their sensitivity to αSN aggregates (37).

We needed to rule out that the reduced toxicity of aggregates formed in the presence of the extracts could be caused by a general effect of the extracts on the cells. Therefore, we treated SH-SY5Y cells with Koroneiki extract, incubated for 2 h, removed the solution and washed with PBS. Subsequently we added αSN aggregates both to extract-treated and untreated cells. We found no significant difference in aggregate toxicity on the two cell types (data not shown), ruling out a general extract effect.

Mitochondrial disruption induced by the aggregates was evaluated by the release of lactate dehydrogenase (LDH) (Fig. 4E). The aggregates formed without the extracts increased LDH release by 60-72 % compared to control. However, LDH release was reduced significantly in cells treated with aggregates formed in the presence of the extracts. This is consistent with reduced cellular toxicity and confirmed that extracts reduce the toxicity of aggregates in the cell-based assays.

In the next step, the membrane permeabilization assay (Fig. 5A) was carried out to see if Koroneiki extract can decrease the membrane-disrupting ability of αSN oligomers, which permeabilize the membrane (and by inference induce toxicity in cells). Fig. 5B shows that Koroneiki extract only leads to an insignificant reduction in oligomer-induced permeabilization of anionic phospholipids in a calcine release assay. The Koroneiki extract itself does not lead to any calcine release and loss of vesicle integrity (data not shown).

We finally tested the Koroneiki extract for its effect on oligomer toxicity in a cellular context (Fig. 5C). Purified oligomers decreased viability by 28 % on their own but only by 15% in the presence of 0.15 mg/ml Koroneiki extract. Thus, Koroneiki extract not only led to formation of less toxic and less cell-permeabilizing oligomers (Fig. 4 B-D), but also protected SH-SY5Y cells against preformed toxic oligomers (Fig. 5C). Koroneiki extract at 0.015 mg/ml did not significantly reduce the toxicity of oligomers (data not shown).

**The Chemical Composition of Different Extracts**

HPLC analysis of the most effective extracts revealed the same qualitative but different quantitative phenolic composition for major components (Fig. S6). For more detailed studies, the Koroneiki extract was fractionated by UHPLC (Fig. S7), after which the inhibitory effect of the fractions was studied and the best fractions in inhibiting αSN fibrillation and reducing toxicity of αSN oligomers were analyzed on LC-MS to identify the compounds involved.
Identification of the Most Effective Fractions

In the first step, the effect of fractions of the Koroneiki extract on αSN fibrillation was studied at two different concentrations. These are designated L and H (Low and High). L and H fractions are obtained from 1 mg/ml and 3 mg/ml Koroneiki extract, respectively, which implies that the concentration of the fractions in the fibrillation assays are much less than 1 mg/ml and 3 mg/ml. The most effective fractions (5, 6 and 17-26) are indicated in red in Fig. S8A and S8B, while the time profiles of fibrillation are shown in Fig. S9. CD and TEM images were used to confirm the ThT data and better understand their effect on αSN fibrillation. CD data (Fig. 6A and 6B) show that the most effective fractions maintained the unfolded secondary structure of αSN. The effect of the fractions at 3 mg/mL on the morphology of endpoint αSN aggregates was analyzed by TEM (Fig. S10). In the presence of the fractions, either only oligomers (f5, 18, 21, 23, and 25) or both short fibrils and oligomers (f6, 17, 19, 20, 24, and 26) were detectable. In contrast, the control sample without the koroneiki extract fractions only showed long straight fibrils.

To determine whether or not the fractions affect elongation of existing fibrils, we incubated monomeric αSN with 5% αSN seeds. Fractions 19, 20, 21, 22, and 23 were the best inhibitors of secondary nucleation (Fig. 6C). The other fractions did not completely inhibit seeded fibrillation but instead decreased the rate of elongation, increasing the time it took for the ThT fluorescence to reach a plateau level.

The effect of the top 12 fractions identified in the ThT assay on the level of small and large oligomers and their ability to disaggregate existing fibrils of αSN was also studied. Fractions 6, 18, 21, 22, 23 led to the formation of more small oligomers (Fig. S11A). Disaggregation of αSN fibrils by Koroneiki fractions also led to the formation of soluble oligomers (Fig. S11B) and fractions 5, 20, 24, 25, 26 were the most effective.

Identification of the Most Effective Fractions Induce the Formation of Less Toxic Aggregates

The same toxicity assay as for whole extracts was used to evaluate the toxicity of formed aggregates during the fibrillation process either in the presence or absence of the Koroneiki fractions. The calcein release assay showed a reduction in the interaction of the aggregates formed up to 24 h in the presence of fractions with the membranes compared to the control samples (Fig. 6D). In the cell assay on both OLN-93 and SH-SY5Y cells, the toxicity of control aggregates formed up to 8 h increased and then decreased slightly. Aggregates formed in the presence of the Koroneiki fractions also generally showed an increase in cytotoxicity at early stages, but the levels of toxicity were reduced compared to control, in particular for fraction 25 (Fig. 6E and F). Overall, the LDH assay in SH-SY5Y cells also confirmed these data (Fig. 6G).

Separation and Identification of Phenolic Compounds in the Most Effective Fractions

We used LC-MS analysis of the most effective Koroneiki fractions to separate and identify major components of these fractions. Identification of the compounds was done based on accurate mass measurements of the [M-H]− ion and their MSMS fragmentation patterns as documented in the literature. The total ion current (TIC) profiles of representative olive fractions are presented in Fig. S13. Data obtained from high resolution MS analysis of the fractions are summarized in Table S2. Data obtained from high resolution MS analysis of the fractions are summarized in Table S2. The major compounds in each fraction are listed in Table S3 and indicated on the TIC profiles of individual fractions (Fig. S13). It is clear that the single largest family of compounds consists of oleuropein and derivatives thereof. For additional insight, we tested individual compounds identified in the Koroneiki fractions, namely verbascoside, loganin, rutin, elenolic acid, 3-Hydroxytyrosol, and oleuropein. The compounds...
effects on αSN fibrillation were tested through ThT-based kinetics, CD spectroscopy and TEM imaging (Fig. 7). ThT data (Fig. 7A) show that verbascoside, elenolic acid, 3-hydroxytyrosol and oleuropein completely inhibit fibrillation at 50 (verbascoside) or 100 µM (all other compounds), comparable to the effect of EGCG (38). The CD data (Fig. 7B) also show that these compounds keep αSN in its monomeric unfolded state better than other compounds. Finally, TEM images of αSN after incubation in the presence of oleuropein confirm the absence of fibrils (Fig. 7C).

**Correlating the Change in the Chemical Compositions of Extracts with their Inhibitory Effect**

We also analyzed extracts from developing fruits to correlate the change in the chemical composition of the extracts with their inhibitory effect. During the ripening process and fruit development, the phenolic content changes (31). Accordingly, we collected olive fruits at different ripening time and the effect of the extracts was tested on αSN fibrillation. The HPLC data and the effect of the extracts are shown at Fig. S14. Then the average values of the end ThT values of αSN aggregation in the presence of different amounts of olive extracts (the 9 top-ranked extracts as well as extracts of fruits collected at different ripening times) were combined with the HPLC data of the olive samples to analyze the effect of different compounds in the extracts. The “peakutils” Python package was used to identify peaks in the HPLC data. Finally, a correlation analysis was performed to determine which peaks have correlated amounts across all of the samples. This analysis confirmed that the compound eluting as oleuropein aglycone, which also shows the highest m-value as a measure of its anti-fibrillation potency, is of interest since the level of that compound was not well correlated with other compounds and was therefore more likely to be responsible for the difference in inhibition across the extracts (Table 1). Comparison of HPLC chromatograms of extracts of fruits picked at different ripening time with their inhibitory effect (Fig. S14) revealed that the extracts with higher level of oleuropein aglycone had more inhibitory potency; in contrast, the levels of other compounds were lower compared to the less effective extracts.

**Discussion**

In PD, αSN aggregation initiates a cascade of molecular events leading to neuronal death. As a consequence, the identification of small molecules able to interfere in vivo with aggregation of αSN is a vital strategy against PD. Here we address three questions to identify olive oils with maximal anti-aggregative effects:

1) What is the mechanism behind the inhibiting effect of beneficial polyphenols?
2) Can these polyphenols lead to the formation of less toxic aggregates?
3) How do the level of beneficial polyphenols change with time?

**The Best Extracts in inhibiting αSN fibrillation Inhibit Both Nucleation and Elongation of αSN**

A summary of the efficacy of the olive extracts and the Koroneiki extract fractions in different assays is shown in Tables 2 and 3, respectively. We scored each assay between 0 and 1 and then determined the final ranking. We classified extracts of 7 out of 15 different olive varieties according to their efficacy in inhibiting distinct steps of αSN aggregation (nucleation and elongation). Although the ranking differed slightly in different assays, all assays emphasized the remarkable inhibitory effect of the Koroneiki extract as the best inhibitor of both nucleation and elongation. Koroneiki, 'the queen of olives', is a variety with particularly good oil quality characteristics, making it the main olive oil produced in Greece (39). Koroneiki and T20 varieties were most effective in the disaggregation assay, whereas Rowghani, which had performed well in the other assays, performed poorly here. These extracts may interact with the hydrophobic residues of β-sheet and cause disaggregation of amyloid fibrils. The different rankings indicate that these extracts are likely to bind both nuclei and fibril surfaces and ends, but to different extents.

**The Best Extracts in inhibiting αSN fibrillation Favor Less Toxic Oligomeric Species**
Inhibition of aggregation could bypass the formation of toxic prefibrillar aggregates and direct αSN towards less toxic aggregates. SEC analysis and SDS-PAGE were used to analyze the aggregates that form in the presence of the extracts. Interestingly, Koroneiki extract, which was the best inhibitor, also ranked top in the formation of small oligomers and only led to a low production of large oligomers, while the T23 extract, which performed poorly in all other assays, strongly favored large oligomers. The SDS-PAGE results also indicate that the great majority of the αSN remains monomeric and the TEM images showed a reduction in longer fibrils at the fibrillation assay endpoint in the presence of the extracts. We therefore conclude that the most promising extracts inhibit αSN amyloidogenesis by retaining αSN in the monomeric state, and incorporating minor amounts of αSN monomers into highly stable oligomers that are non-cytotoxic and off-pathway to fibrillogenesis (16), thereby inhibiting the subsequent growth phase (Fig. 8).

This change in the aggregation process also reduces cytotoxicity. Co-incubation of monomeric αSN with Koroneiki extracts lead to the formation of aggregates that – particularly after longer incubation - permeabilized membranes significantly less than the control aggregates and were less toxic to OLN-93 and particularly to SH-SY5Y cells. Some compounds are known to inhibit the membrane interactions of preformed αSN oligomers that are non-cytotoxic and off-pathway to fibrillogenesis (16), thereby inhibiting the subsequent growth phase (Fig. 8).

αSN is susceptible to oxidative stress which in turn favors its aggregation (41), and oligomeric species formed in the aggregation process can induce oxidative stress (42). Therefore, extracts and compounds that inhibited both αSN aggregation and reactive oxygen species (ROS) production would be promising. The extracts themselves showed no toxicity to OLN-93 and SHSY5Y cells. All extracts showed significant antioxidant activity and neutralized the deleterious effect of H2O2 on cells with different potency. This protective effect other than the scavenging of free radicals could be due to the effect at the molecular level of the cells such as activation of signaling cascades and regulation of calcium ion homeostasis (43).

**Oleuropein aglycone, Hydroxyoleuropein aglycone, and Oleuropein Are Mainly Responsible for the Difference in Inhibition across the Extracts**

An understanding of the molecular mechanism of olive extract-induced inhibition is complicated by the polyphenolic complexity as evidenced by LC-MS. In addition to polyphenols, such as flavonoids found in many fruits, oleuropein and other glucosides structurally related to this compounds are present exclusively in olive plants. Using the same assays as used for ranking the extracts, the inhibitory effect of fractions of the Koroneiki extract was tested on αSN fibrillation. Phenolic compounds present in the inhibitory extracts were identified as hydroxytyrosol, hydroxytyrosol glucoside, oleuside, rutine, verbascoside, 6′-(E)-p-coumaroyl-secologanoside, and compounds structurally related to oleuropein, such as dihydrooleuropein, hydroxyoleuropein, oleuropein glucoside, hydroxyoleuropein aglycone, and oleuropein aglycone (Table S3). Some of these compounds are commercially available and the others can be chemically synthesized or isolated from olive sources. The effects of some of the compounds on fibrillation of proteins and their antioxidant potency have been studied before (22–24). The fractions containing the most effective compounds were ranked in different assays (Table S5). As shown for the extracts, the isolated fractions also have different effects in the assays used in this study (Table 3). Some extracts have more fibrillation inhibitory potency (f5, 19, 20, 21, 22, 24), some are better in inhibition elongation (f5, 6, 19, 20, 21, 22), some produce more small oligomers (f18, 21, 22), some are more effective in disaggregation of preformed fibrils (f5, 20, 24, 25, 26), and some of them were excellent in decreasing the formation of toxic aggregates (f5, 17, 20, 21, 26). Interestingly, all the fractions with the highest inhibitory effect (f5, 6, 17-26) showed higher ROS scavenging ability.
HPLC analysis showed that the content of the polyphenols of olive fruit depends on olive cultivar and ripening stage of the fruit, which leads to a different effect on the fibrillation process and the formed αSN species, antioxidant activity and ROS scavenging and toxicity. To correlate the change in the polyphenol content of the extracts with their inhibitory effect, we compared the level of the compounds based on the height of the peaks in each extract with the end ThT values in a correlation analysis (Table 1). This analysis shows that oleuropein aglycone, hydroxyoleuropein aglycone, and oleuropein are the main compounds responsible for the difference in inhibition across the extracts. Koroneiki as the most inhibitory cultivar contains the maximum level of oleuropein aglycone compared to the other varieties. This correlation in the extracts of same varieties picked at different ripening stages is also clear. Most of the compounds in olive oil result from spontaneous oleuropein hydrolysis and processing (44). The hydrolysis of oleuropein by an endogenous β-glycosidase during ripening leads to formation of oleuropein aglycone, which is the key compound responsible for the protective effect of olive oils. There are other studies on the inhibitory effect of oleuropein aglycone on fibrillation of aggregation-prone proteins. Palazzi et al (27) recently demonstrated that oleuropein aglycone hampers the growth of on-pathway αSN oligomers and favors growth of stable and harmless aggregates. Further, oleuropein aglycone reduces the toxicity of αSN aggregates by interfering with their binding to cell membrane components. These data are in accordance with our own findings that olive compounds rescue cells from the toxicity of αSN aggregates. Oleuropein aglycone also interferes with the in vitro aggregation of human amylin and Aβ42 and redirects the aggregation pathway towards non-toxic aggregates, and interferes with Aβ42 proteotoxicity in vivo in transgenic C.elegans strains expressing Aβ42 by reducing plaque load and motor defect (20, 44, 45).

In summary, we conducted a systematic study of the effect of fruit extracts of different olive varieties on αSN fibrillation, oligomerization and toxicity, and antioxidant activity to select phenol-rich olive varieties with maximal effective phenolic content to counteract the development of PD hallmarks. We conclude that the polyphenols in olive fruits play a significant role in protection against PD. More specifically, we conclude that polyphenols can reduce αSN aggregate toxicity through their antioxidant activity and direct aggregation towards non-toxic species. Our results contribute to the wider discussions concerning the mechanism of action of polyphenols in aggregation and toxicity prevention. Evaluation of the protection against PD by olive extracts and polyphenols in cell and animal models and development of nanocarriers to increase the bioavailability of olive polyphenols would be an interesting further step to drug development for PD. This will be useful not only for PD but also for assessing the potential of polyphenols in olive oils for future applications.

**Experimental procedures**

**Materials**

Penicillin–streptomycin, fetal bovine serum (FBS), and Dulbecco’s Modified Eagle Medium (DMEM) were purchased from Gibco BRL (Gaithersberg, MD, USA). 1,2-dioleoyl-sn-3-phosphatidyl-glycerol (DOPG) were from Avanti Polar Lipids (Alabaster, AL). Lactate dehydrogenase (LDH) measurement kit was from Pishtazteb Co. (Iran). All other chemicals were from Sigma Aldrich (St. Louis, MO).

**Olive Fruit Samples**

Three distinct categories of olive varieties were studied (Table S1). The first group, the Tarom varieties (T), consists of nine Iranian olive varieties including T10, T15, T16, T17, T18, T20, T22, T23 and T24 (46). The second group consists of three Mediterranean varieties including Koroneiki, Arbequina and Picual. The third group consists of three major varieties in Iran including Zard, Mari, and Rowghani. All the studied olive trees were nearly 18 years old, reproduced by taking cuttings from the mother plant, irrigated and fertilized by a drip system at Tarom olive research station. All trees samples were in the same orchard under the same environmental conditions. Three replicated plants were studied. The fruits were picked at 180 days after full bloom (DAFB) corresponding to
different developmental stages for the different olive tree varieties. Samples were stored at -20°C on the same day of picking (47).

**Extraction of Phenolic Compounds From Olive Fruits**

The fresh mesocarp (3 g) was frozen in liquid nitrogen and ground to fine powder in a porcelain mortar. It was then mixed with methanol (12 mL) and vortexed for 1 min at 20°C. The resulting mixture was centrifuged (3500 rpm at 4°C) for 20 min. The supernatant was separated, lyophilized and stored at -20 °C.

**Protein Production and Purification**

Recombinant human αSN was expressed in *Escherichia coli* BL21(DE3) strain with a plasmid vector pET11-D using auto-induction (48). Briefly, the pelleted cells were resuspended in 100 mL osmotic shock buffer (30 mM Tris-HCl, 40 % sucrose, 2 mM EDTA, pH 7.2), and incubated for 10 min followed by centrifugation (9000 g, 20 °C, 30 min). The resulting pellet was resuspended in 90 mL ice-cold deionized water and 40 µL of saturated MgCl2 was added, followed by incubation on ice for 3 min. The supernatant after centrifugation (9000 g, 4 °C, and 20 min) was precipitated by titration with 1 M HCl to pH 3.5 and then incubated for 5 min. The supernatant after centrifugation (9000 g, 4 °C, and 20 min) was precipitated by titration with 1 M HCl to pH 3.5 and then incubated for 5 min. The supernatant after centrifugation (9000 g, 4 °C, and 20 min) was precipitated by titration with 1 M HCl to pH 3.5 and then incubated for 5 min.

**Protein and Extract Handling**

Prior to use, freshly dissolved αSN in PBS buffer, pH 7.4, was filtered (0.2 µm). Protein concentration was measured by absorbance measurements at 280 nm with a NanoDrop™ 1000 spectrophotometer (Thermo Scientific) using a theoretical extinction coefficient of 0.412 (mg/mL)1. All olive fruit extracts used in the screening assays were freshly dissolved in PBS buffer and filtered (0.2 µm) prior to use.

**Plate Reader Fibril Formation Assays**

αSN fibril formation was carried out as described (33). Briefly, 150 µL PBS solution containing 70 µM (1 mg/ml) αSN, 40 µM ThT and varying amounts of methanolic olive extracts was added to each well of a 96-well-plate (Nunc, Thermo Fischer Scientific, Roskilde, Denmark) with a 3 mm diameter glass bead, sealed with Crystal clear sealing tape (Hampton Research, Aliso Viejo, CA, USA). The fibrillation was followed at a Genios Pro fluorescence plate reader (Tecan, Mänedorf, Switzerland) at 37 °C with 300 rpm orbital shaking between the readings for 12 min. Samples were excited at 448 nm and emission was measured at 485 nm.

The dose-response aggregation inhibition curves fitted a simple binding isotherm:

\[ \text{ThT}_{\text{end level}} = \left( \text{ThT}_{0} - \text{ThT}_{\text{min}} \right) \left( 1 - \frac{[\text{Olive extract}]}{K_D + [\text{Olive extract}]} \right) + \text{ThT}_{\text{min}} \]  

where ThT_{end level} is the ThT fluorescence level at the end of the fibrillation process at a given olive concentration, ThT0 is the ThT fluorescence end level in the absence of compounds, ThT_{min} represents the ThT level at maximum inhibition, [Olive extract] is the concentration of the olive extract and K_D is the mole ratio needed for half inhibition.

The Finke-Watzky (F-W) (49) equation was fitted to the normalized ThT fibrillation data:

\[ F(t) = \frac{1}{1 + e^{-\frac{t}{\nu(t-t_1/2)}}} \]  

\[ t_N = t_{1/2} - \frac{1}{\nu} \]  

where \( t_1/2 \) is the time required to produce half the total product, \( \nu \) is the rate of growth at \( t_1/2 \) and \( t_N \) is the duration of the nucleation (lag) phase (31).

**Seeding Experiments**

The fibril elongation assays were performed using a plate reader setup with the same settings as for the fibrillation assay in the presence of 0.05 mg/mL seeds (corresponding to 3.5 µM monomer) and 0.15 mg/ml olive extracts in a solution of 70 µM monomeric αSN in 96-well plates. The snap-frozen mature fibrils were thawed and fragmented by sonication for 2 min on ice (pulse 5 s. on and 5 s. off) with an amplitude of 20 % on a QSonica Sonicators (Q500, Newtown, CT, USA) to obtain short fibrils, which were employed as seeds.
Fibril Disaggregation Assays

The fibril stock solution was prepared using the same setting as for the fibrillation assay and the fibrils. Aggregated αSN (35 μM monomer equivalents) was incubated overnight either alone or with the olive extracts (0.15 mg/mL) at 37 °C. The solution was centrifuged (21000 g, 20 min) and the supernatant was injected onto a 24 mL Superose 6 10/300 gel filtration column (GE Healthcare Lifescience) at 0.5 mL/min to separate monomers and oligomeric species.

Preparation of Oligomers

αSN oligomers were prepared as previously described (16). Briefly, 12 mg/mL αSN was incubated in PBS buffer for 5 h at 37 °C and 900 rpm on an Eppendorf thermoshaker, TS-100, BioSan, Latvia. The sample was then centrifuged (21000 g, 10 min) to remove insoluble material and the supernatant was loaded on an a Superose 6 Prep Grade column, GE healthcare Life Sciences, Sweden, in PBS at 2.5 mL/min. Small oligomers were collected and were concentrated with 15 mL Amicon ultracentrifugal filters (Merck).

Preparation of Large Unilamellar Vesicles (LUVs)

LUVs were prepared as described (50). Briefly, 1, 2-dioleoyl-sn-3-phosphatidylglycerol (DOPG), or 1,2-dimyristoyl-sn-glycero-3-phospho-(1’-rac-glycerol) (sodium salt) (DMPG) was dissolved at 5 mg/ml in PBS. The solution was subjected to 10 freeze thaw cycles between liquid nitrogen and a 50 °C water bath. The lipid solution was extruded 21 times through a 100 nm filter. To prepare calcein loaded vesicles, calcein at self-quenching concentrations (70 mM) was added to the phospholipids and after extrusion, the vesicle solution was run through a PD-10 desalting column (GE Healthcare) to separate free calcein from calcein loaded vesicles.

Analyzing Soluble αSN Remaining in Solution

To analyze soluble αSN remaining in the solution, samples were taken from the plate after 24 h incubation and pelleted by centrifugation for 10 min at 21000 g. This speed can pellet large fibrillar aggregates, leaving in the supernatant monomers and oligomers which do not even pellet during ultracentrifugation unless bound to e.g. phospholipid vesicles (51). We are able to discriminate monomers and oligomers by SDS-PAGE since the latter are SDS-resistant (10). The supernatant was mixed with SDS-PAGE sample loading buffer and heated for 2 min at 95 °C before loading on a 15% SDS-PAGE gel. The supernatant was also run on a Superose 6_10/300 gel filtration column.

Circular Dichroism (CD) Spectroscopy

For far-UV CD, sonicated fibril solutions with protein concentration of 0.2 mg/mL (14 μM) were placed in a 1 mm cuvette and the spectra were measured from 250 to 195 nm at 25 °C with a Jasco J-810 spectrophotometer (Jasco Spectroscopic Co., Ltd., Japan). To measure the induced changes in the secondary structure of αSN by DMPG vesicles and the effect of olive samples on this interaction, 0.2 mg/mL (14 μM) of αSN was mixed with 0.2 mg/mL of DMPG vesicles in the presence and absence of 0.15 mg/ml of olive samples in PBS buffer at 37 °C. CD spectra of PBS buffer and the olive solutions were recorded and subtracted from the protein spectra and the CD signal given as mean residue ellipticity (degrees cm² dmol⁻¹).

Transmission Electron Microscopy (TEM)

αSN sample in 5 μL PBS buffer was transferred to a carbon-coated, glow-discharged 400-mesh grid for 30 s. The grids were washed using 2 drops of double distilled water, stained with 1% (w/v) phosphotungstic acid (pH 6.8), and blotted dry. The samples were viewed in a microscope (JEM-1010; JEOL, Tokyo, Japan) operating at 60 kV. Images were obtained using an Olympus KeenView G2 camera.

Oligomerization Assays

αSN monomer (1 mg/mL) was incubated on an Eppendorf TS-100 thermoshaker (BioSan, Latvia) with 0.15 mg/mL of olive extracts for 1 h at 37 °C and 900 rpm. The solution was centrifuged (21000 g, 20 min) and the supernatant was injected into a 24 mL Superose 6 10/300 gel filtration column at 0.5 mL/min. Samples from both oligomerization and disaggregation assays were run on an SEC-MALS system (Wyatt Technology Europe) using separation on a Superose 6_10/300 gel filtration column and analyzed using 18-angle static laser light
scattering (Dawn Heleos II), refractive index (Optilab T-rEX differential refractometer) and absorbance at 280 nm (Agilent 1260 Analytical UV cell). Data was collected and analysed using the software ASTRA 6.1.7.17 (Wyatt Technology Europe).

Calcein Release Assays

The membrane permeabilization assay was carried out to compare the membrane-disrupting ability of different αSN aggregates that form in the presence and absence of the extracts. Oligomers permeabilize the membrane (and by inference induce toxicity in cells) much more efficiently than fibrils. Permeabilization of vesicles due to the interaction with oligomers results in calcein release and an increase in the fluorescence signal due to dilution. Calcein-loaded DOPG vesicles at a final lipid concentration of 42 µM were loaded in triplicate in a 140 µL assay solution onto a 96-well plate (Nunc, Thermo Fisher Scientific, Roskilde, Denmark). The background fluorescence at excitation 485 nm and emission at 520 nm was measured on Genios Pro fluorescence plate reader (Tecan, Mänendorf, Switzerland) before and after addition of vesicles. The olive extracts and/or oligomers at a final concentration of 0.02-0.2 mg/mL and 0.5 µM, respectively, were mixed with vesicles in a final volume of 150 µL. The plates were sealed with crystal clear sealing tape (Hampton Research, Aliso Viejo, CA, USA) and calcein release was measured for 1 h at 37 °C every 1.5 min with 2-s autoshake before each reading. Finally, 1 µL Triton X-100 (0.1% (w/v)) was added to lyse vesicles, leading to complete calcein release and maximal fluorescence signal. Background fluorescence was subtracted.

HPLC Analysis of Phenolic Compounds in Different Olive Fruit Extracts

The extracts were analyzed with an Ultimate 3000 model HPLC, run on a RP-C18 Luna column, 4.6 mm id×250 mm and particle size 5 µm (Phenomenex, UK). For each injection (50 µL), elution was performed at a flow rate of 1 mL/min, using a solvent system of water/TFA (1%) (A) and acetic acid/TFA (1%) (B). Elution was started with 5 % B at 45 min, 90 % B at 55 to 57 min and then reduced to 5 % B at 61 min. Chromatograms were recorded at 230 nm.

Fractionation of Koroneiki Extracts by HPLC

Dried extracts were reconstituted using 1.75 mL of water. Fractionation was carried out using an HPLC system (Dionex UltiMate 3000, Thermo Fisher Scientific) equipped with an Ascentis C-18 column (5 µm, 5 × 250 mm, Supelco, UK). Chromatographic separation was performed using a constant flow rate of 1 mL/min of the mobile phases water/0.1% formic acid (A) and acetonitrile/0.1% formic acid (B). The binary gradient was: 0–10 min, 5% B; 10–50 min, 22% B; 50–60 min, 37% B; and finally 60–70 min, 50% B. Fractions were collected every 2.5 min between 5 and 70 min (T1-T26). Twelve injections (100 µL each) were performed and fractions from repeated runs were combined. Thirty µL of each fraction was diluted with 270 µL of 80/20 (v/v) water/methanol and subsequently analysed by UHPLC-MS. The remainder of each fraction was dried using a Speedvac concentrator (Genevac, Suffolk, UK).

Identification of Phenolic Compounds in Koroneiki Extract Fractions by uHPLC-MS

To identify the compounds, Ultra High Performance Liquid Chromatography-Mass Spectrometry (uHPLC-MS) were recorded with an Ultimate 3000 RS uHPLC system, equipped with a DAD-3000 photodiode array detector, coupled to an LTQ-Orbitrap Elite mass spectrometer (Thermo Scientific, Germany). An injection volume of 10 µL was used and the elution was performed on a reversed-phase C18 Hypersil gold column (1.9 µm, 30 x 2.1 mm i.d., Thermo, Hemel Hempstead, UK), at 35 °C, using a solvent system consisting of water/0.1% formic acid (A) and acetonitrile/0.1% formic acid (B) under the following conditions: 0–5 min, 0% B; 5–27 min, 31.6% B; 27–34 min, 45% B; 34–37.5 min, 75% B at a flow rate of 0.3 mL/min. Mass spectra were collected using an LTQ-Orbitrap Elite with a heated ESI source (Thermo Scientific, Germany). Mass spectra were acquired in negative mode with a resolution of 120,000 over m/z 50-1500. The source voltage, sheath gas, auxiliary gas, sweep gas and capillary temperature were set to 2.5 kV, 35 (arbitrary units), 10 (arbitrary units), 0.0 (arbitrary units)
and 350 °C respectively. Default values were used for other acquisition parameters. Automatic MS-MS was performed on the 4 most abundant ions using an isolation width of m/z 2. Ions were fragmented using high-energy C-trap dissociation (HCD) with a normalized collision energy of 65 and an activation time of 0.1 ms. Data analysis was carried out using Xcalibur v. 2.2 (Thermo Scientific, Germany). Compounds were identified on the basis of their retention time, accurate mass and MSMS fragmentation patterns. Where possible, known compounds were compared to authentic standards if available. Where this was not possible, a comparison to the reported MSMS fragmentation data was made for known compounds. Compounds where structural data could not be verified were labelled as unknown. A full table of the LC-MS data was prepared, including details of identification method for each component and reference data for known compounds (Table S2).

**Antioxidant Activity**

The antioxidant activity of the olive extracts was determined by monitoring the disappearance of DPPH• in the presence of olive extracts at 517 nm. Olive extracts (20 µl) at various concentrations was mixed with 200 µl of DPPH• solution (0.135 mM). The resulting medium was incubated at room temperature in darkness for 30 min. The antioxidant activity was determined using the following formula:

\[
\text{Antioxidant activity} = \left( \frac{\text{Abs}_{517\,\text{control}} - \text{Abs}_{517\,\text{sample}}}{\text{Abs}_{517\,\text{control}}} \right) \times 100 (4)
\]

**ROS assay**

To assess whether olive extracts interfered with the level of ROS within the cells, 2’, 7’-dichlorodihydrofluorescein diacetate (DCFH-DA) was used. OLN 93 cells were seeded in 96-well plates at a density of 6×10⁴ cells/mL and incubated in a humidified atmosphere incubator at 37°C for 24 h. The medium was then removed and the cells washed with PBS and replaced by PBS containing 15 µM DCFH-DA. The plate was incubated for 45 min in the dark in a CO₂ incubator. DCFH-DA was removed and the wells were washed with PBS, treated with culture medium containing olive extracts in the absence or presence of 100 µM H₂O₂ and incubated at 37°C (for 1 h) after which fluorescence of DCF was recorded in a microtiter plate reader (excitation / emission: 490/527 nm).

**Evaluation of Cell Viability**

The 3-[4, 5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay was implemented to measure cellular viability after 24 h treatment by monomeric or aggregated forms of αSN. OLN-93 and SH-SY5Y cells were seeded in 96-well plates at a concentration of 30×10³ and 60×10³ cells/mL, respectively, in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10 % (v/v) fetal bovine serum (FBS), 100 units/mL penicillin, and 100 µg/mL streptomycin and cultured for 24 h. The medium was then replaced with fresh medium containing different concentrations of olive extracts or with 12.5 % αSN samples (collected during the fibrillation process). After 24 h at 37 °C, the old medium was replaced with fresh medium containing 10 % MTT (5 mg/mL), and the plates were incubated for an additional 4 h at 37 °C. To avoid possible interference between antioxidant compounds and the MTT assay, the cells were washed to remove aggregates and compounds before adding MTT. The formazan crystals were dissolved in 100 µL DMSO by incubating for 1 h on a shaking table at room temperature. Finally, absorbance was determined by a plate reader at 570 nm using 650 nm as a reference wavelength. Cell viability was calculated as follows:

\[
\text{Cell viability} (%) = \left( \frac{\text{Abs}_{570\,\text{control}} - \text{Abs}_{570\,\text{sample}}}{\text{Abs}_{570\,\text{control}}} \right) \times 100 (5)
\]

**LDH Assay**

Release of cytoplasmic enzyme, lactate dehydrogenase (LDH), as the sign of loss of membrane integrity was measured. After the treatment of the cells with αSN samples, 100 µL of growth medium was added to 1 mL of the kit substrate and absorbance at 340 nm was determined for 4 min to follow the conversion of NADH to NAD⁺. The values were expressed as a percentage of the untreated cells as control.

**Analysis of HPLC Elution Profiles**

The average values of the end ThT values of αSN aggregation in the presence of different concentrations of olive extracts and HPLC data of the olive extracts were used to analyze the effect of different compounds in the olive fruit extracts.
The “peakutils” Python package (https://bitbucket.org/lucashnegri/peakutils) was used to identify peaks in the HPLC data and the “sklearn” Python package (http://scikit-learn.org/stable/) to cluster them as follows:

a. The threshold for identifying peaks (the minimum height) was set to 750 A.U.

b. The minimum distance between peaks was set to 50 data points.

c. All of the peaks identified in this way (across all of the datasets) were compiled into a single list of peaks, and a k-means clustering was used to cluster the peaks into 5 groups.

d. The cluster centers were extracted and used to identify the peaks in further analyses.

For each peak that was identified, a relative measure of the “amount of compound” in each sample was determined by multiplying the concentration of the extract (mg/mL) by the height of the peak. Where the data was available, the “amount of compound” was plotted against the ThT signal. Data points with ThT signals below 1000 (arbitrary unit) were excluded from further analysis under the assumption that these corresponded to maximal inhibition and therefore might obscure attempts to determine whether the concentration of the compound was related to the level of the ThT signal in the relevant range (between 7000 and 1000 units). For each compound, the coefficient of determination ($R^2$), and Spearman’s rank correlation coefficient were computed, and an isotonic regression model was built from the data. The $R^2$ value measures the goodness of fit assuming a linear model, while the Spearman’s rank correlation coefficient measures how monotonically related the two quantities are without making an assumption about the functional form of the relation. R-squared values are always positive and between 0 and 1. Spearman R values can be in the range of -1 to 1. The isotonic regression generates an optimal monotonic fit to the data. The slope of the optimal linear fit (the m-value) was taken as a measure of potency, with larger (negative) slopes corresponding to more potent inhibition. Finally, a correlation analysis was performed to determine which peaks had correlated amounts across all of the samples.

**Statistical Analysis**

Data were obtained in triplicate and averaged. The results are shown as mean ± standard deviation (SD). Statistical differences between group means were analyzed by analysis of variance (ANOVA). A value of p < 0.05 was considered statistically significant.

**ACKNOWLEDGEMENTS**

H.M.B., F.A., and D.M were supported by the grant 982 from Center for International Scientific Studies & Collaboration (CISSC). H.E., N.P.S., C.S., I.M.M., G.C., and D.E.O. were supported by grant 4005-00082 from the Independent Research Fund Denmark | Technology and Production. C.L., A.T., and J.L.W were supported by a grant that Rothamsted Research received from the Biotechnology and Biological Sciences Research Council (BBSRC) of the UK. J.W. received funding from the Tailoring Plant Metabolism Institute Strategic Programme grant [BB/E/C/00010410], funded by the BBSRC.

**CONFLICT OF INTEREST**

The authors declare that they have no conflicts of interest with the contents of this article.

**References**


NPs) alter alpha-synuclein conformation and aggregation kinetics. *Nanoscale* 7, 19627–19640


Table 1. For each olive extract constituent, coefficient of determination ($R^2$), the slope of the optimal linear fit (m-value) and Spearman’s rank correlation coefficient for each compound.

<table>
<thead>
<tr>
<th>Peak elution time</th>
<th>Compound</th>
<th>R-Squared$^a$</th>
<th>m-value$^b$</th>
<th>Spearman R$^c$</th>
</tr>
</thead>
<tbody>
<tr>
<td>35.5</td>
<td>Oleuropein</td>
<td>0.29</td>
<td>-11.76</td>
<td>-0.73</td>
</tr>
<tr>
<td>28.5</td>
<td>Verbascoside</td>
<td>0.39</td>
<td>-24.69</td>
<td>-0.71</td>
</tr>
<tr>
<td>50.3</td>
<td>Oleuropein aglycon</td>
<td>0.48</td>
<td>-88.31</td>
<td>-0.76</td>
</tr>
<tr>
<td>40.0</td>
<td>Hydroxyoleuropein aglycone</td>
<td>0.24</td>
<td>-24.13</td>
<td>-0.72</td>
</tr>
</tbody>
</table>

$^a$ Coefficient of determination: measures the goodness of fit assuming a linear model.
$^b$ The slope of the optimal linear fit (the m-value): measures the potency with larger (negative) slopes corresponding to more potent inhibition.
$^c$ Spearman’s rank correlation coefficient: measures how monotonically related the two quantities are without making an assumption about the functional form of the relation.
Table 2. Ranking of the top 7 olive variety extracts in different assays.

<table>
<thead>
<tr>
<th>Assay</th>
<th>T10</th>
<th>T17</th>
<th>T20</th>
<th>T23</th>
<th>T24</th>
<th>Rowghani</th>
<th>Koroneiki</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhibiting aggregation (^a)</td>
<td>++++</td>
<td>++</td>
<td>+++</td>
<td>++</td>
<td>+++</td>
<td>++++</td>
<td>++++</td>
<td>Fig. 1</td>
</tr>
<tr>
<td>Inhibiting secondary nucleation (^b)</td>
<td>++++</td>
<td>+++</td>
<td>++++</td>
<td>++</td>
<td>+++</td>
<td>+++</td>
<td>++++</td>
<td>Fig. 3</td>
</tr>
<tr>
<td>Formation of small oligomers (^c)</td>
<td>+++</td>
<td>+++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++++</td>
<td>Fig. 3</td>
</tr>
<tr>
<td>Formation of large oligomers (^d)</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++++</td>
<td>++</td>
<td>+++</td>
<td>+</td>
<td>Fig. 3</td>
</tr>
<tr>
<td>Inducing formation of less toxic aggregates to SH-SY5Y cells during fibrillation (^e)</td>
<td>++++</td>
<td>++++</td>
<td>+++</td>
<td>+++</td>
<td>++++</td>
<td>++++</td>
<td>++++</td>
<td>Fig. 4</td>
</tr>
</tbody>
</table>

\(^a\) at 0.1 mg/ml of the olive extracts, + denotes 0-25 % inhibition, ++ 25-50 % inhibition, +++ 50-75 % inhibition, and ++++ 75-100 % inhibition.

\(^b\) at 0.15 mg/ml of the olive extracts, + denotes 0-25 % inhibition, ++ 25-50 % inhibition, +++ 50-75 % inhibition, and ++++ 75-100 % inhibition.

\(^c\) at 0.15 mg/ml of the olive extracts, Min [small oligomer] = A, Max [small oligomer] = B, \(x = \frac{A-B}{4}\).

\(^d\) The same formula for ranking as in note c, this time using the large oligomers.

\(^e\) Average of toxicity of aggregates formed over different time ranges compared to control.
Table 3. Ranking of the fractions in different assays.

<table>
<thead>
<tr>
<th>Assay</th>
<th>5</th>
<th>6</th>
<th>17</th>
<th>18</th>
<th>19</th>
<th>20</th>
<th>21</th>
<th>22</th>
<th>23</th>
<th>24</th>
<th>25</th>
<th>26</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhibiting aggregation a</td>
<td>+++</td>
<td>++</td>
<td>++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>++</td>
<td>++</td>
<td>Fig. 6</td>
</tr>
<tr>
<td>Inhibiting secondary nucleation b</td>
<td>+++</td>
<td>+++</td>
<td>++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>++</td>
<td>++</td>
<td>Fig. 6</td>
</tr>
<tr>
<td>Formation of small oligomers c</td>
<td>++</td>
<td>+++</td>
<td>++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>++</td>
<td>++</td>
<td>Fig. S11</td>
</tr>
<tr>
<td>Inducing formation of less toxic aggregates to SH-SY5Y cells during fibrillation d</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>Fig. 6</td>
</tr>
</tbody>
</table>

a at 0.1 mg/ml of the olive extracts, + denotes 0-25 % inhibition, ++ 25-50 % inhibition, +++ 50-75 % inhibition, and ++++ 75-100 % inhibition.
b at 0.15 mg/ml of the olive extracts, + denotes 0-25 % inhibition, ++ 25-50 % inhibition, +++ 50-75 % inhibition, and ++++ 75-100 % inhibition.
c at 0.15 mg/ml of the olive extracts, Min [small oligomer] = A, Max [small oligomer] =B, x = \( \frac{A-B}{4} \).
d Average of toxicity of aggregates formed over different time ranges compared to control.
Fig. 1. The effect of the extracts on αSN fibrillation. (A) The effect of 0-0.3 mg/ml of the olive extracts on the kinetics of αSN fibrillation at 5 different concentrations monitored by ThT fluorescence. Joined lines show Finke-Watzky model fitted to the experimental data. (B) The effect of the selected extracts (7 out of 15 extracts) at different concentrations (0.025, 0.05, 0.1, 0.15, and 0.3 mg/ml) on the maximum ThT fluorescence intensity. (C) ThT end-point levels are converted to % inhibition and fitted to Eq.1 to calculate the IC50 of the extracts. (D-F) Kinetic parameters for αSN fibrillation as a function of various concentration of the extracts relative to the values in the absence of the extracts ((D) relative growth rate (ν/ν_control), (E) relative half time (t½/t½_control), and (F) relative lag time (tN/tN_control)).
Fig. 2. Far-UV CD spectra of αSN incubated alone (control) and in the presence of (A) 0.3 mg/ml, (B) 0.15 mg/ml, and (C) 0.1 mg/ml of the 7 selected extracts after 24 h. (D) Normalized β structure (%) of αSN incubated in the presence of the 7 selected extracts. (E) SDS-PAGE analysis of the supernatants of the incubated samples of αSN in the absence and presence of 0.15 and 0.3 mg/ml of the best extracts in inhibiting αSN fibrillation. Monomeric αSN has a molecular weight of 14.5 kDa. Arrows highlight dimers (≈35 kDa) and oligomers (> 250 kDa). (F) The SEC-profile of the supernatants of the samples of αSN incubated for 24 h with or without 0.15 mg/ml of Koroneiki extract. (G) Electron microscopy of αSN after 24 h incubation in the absence (control) and presence of 0.3 mg/ml of the 7 selected olive fruit extracts. Scale bar, 200 nm. The size and distribution of the fibrils in each sample are summarized in the table below Fig. 2G. The length of fibrils were obtained in three TEM images for each sample and averaged.
Fig. 3. The SEC-profile of the supernatants of the (A) samples of αSN incubated for 1 h and (B) preformed αSN fibrils preincubated overnight with or without 0.15 mg/ml of Koroneiki extract. The effect of the extracts (0.15 mg/ml) on the seeding of αSN aggregation under (C) shaking and (D) non-shaking condition. (E) Schematic representation of the α-helix structure induced in αSN by DMPG vesicles. (F) The effect of the extracts (0.15 mg/ml) on the interaction of monomer (14 µM) and DMPG vesicles (0.2 mg/ml).
Fig. 4. (A) Schematic representation of the effect of olive variety extracts on the membrane permeabilization and cytotoxicity of αSN aggregates. (B) Calcein release from DOPG vesicles after 20 min incubation with αSN aggregates formed alone and in the presence of the best extracts (0.3 mg/ml) over different times (0-24 h). Viability of (C) OLN-93 and (D) SH-SY5Y cells after 2-24 h incubation with αSN aggregates formed alone and in the presence of the best extracts (0.3 mg/ml) over different times (0-24 h). (E) Cytotoxicity of αSN aggregates to SH-SY5Y cells was assayed by LDH-release. LDH signals were normalized to untreated cells. For all assays, values represent means ± SD and the differences between the groups and αSN control are significant (P < 0.05) unless marked “ns”.
Fig. 5. (A) Schematic representation of the effect of Koroneiki extract fractions on the membrane permeabilization and cytotoxicity of αSN aggregates. (B) Calcein release from DOPG vesicles induced by oligomers (0.1 µM) either alone or in the presence of Koroneiki (0.2 mg/ml). The Koroneiki extract is used at the highest concentration at which quenching of fluorescence does not happen. (C) Viability of SH-SY5Y cells incubated with αSN oligomers with or without co-incubation with Koroneiki (0.15 mg/ml).
Fig. 6. (A) Far-UV CD spectra of αSN incubated alone (control) and in the presence of 3 mg/ml of Koroneiki extract fractions. (B) Normalized β structure (%) of αSN incubated in the presence of Koroneiki extract fractions. (C) The effect of the Koroneiki extract fractions (1.5 mg/ml) on the seeding of αSN aggregation under shaking conditions. (D) Calcein release from DOPG vesicles after 20 min incubation with αSN aggregates formed alone and in the presence of Koroneiki extract fractions (3 mg/ml) over different times (0-24 h). Viability of (E) OLN-93 and (F) SH-SY5Y cells after 24 h incubation with αSN aggregates formed alone and in the presence of Koroneiki extract fractions (3 mg/ml) over different times (0-24 h). (G) Cytotoxicity of αSN aggregates to SH-SY5Y cells was assayed by LDH-release. LDH signals were normalized to untreated cells. For all assays, values represent means ± SD and the differences between the groups and αSN control are significant (P < 0.05) unless it has "ns" mark.
Fig. 7. The effect of Koroneiki compounds on fibrillation of 1 mg/ml αSN. (A) The kinetics of αSN fibrillation in the presence of 0-200 µM of Koroneiki compounds, monitored by ThT fluorescence. (B) Far-UV CD spectra of αSN incubated alone (Ctrl) and in the presence of 200 µM of Koroneiki compounds after 24 h. (C) Electron microscopy of αSN after 24 h incubation in the presence of 200 µM oleuropein. Scale bar: 200 nm.
Fig. 8. Schematic representation of screening of different olive varieties. (1) The first screening of fruit extract of 15 different olive varieties on the kinetic analysis of αSN fibrillation. (2) The most effective variety, Koroneiki, combined strong inhibition of αSN fibril nucleation and elongation with strong ability to disaggregate preformed fibrils and prevent formation of toxic αSN oligomers. (3) Koroneiki fruit extract was fractionated and by using the same assay as the ones used in step 2, the most effective fractions were identified. LS-MS analysis was further used to identify the major compounds in the effective fractions. Correlation analysis confirmed oleuropein aglycone, hydroxyoleuropein aglycone, and oleuropein as key compounds responsible for the difference in inhibition across the extracts.
Oleuropein derivatives from olive fruit extracts reduce α-synuclein fibrillation and oligomer toxicity

Hossein Mohammad-Beigi, Farhang Aliakbari, Cagla Sahin, Charlotte Lomax, Ahmed Tawfike, Nicholas P. Schafer, Alireza Amiri-Nowdijeh, Hoda Eskandari, Ian Max Møller, Mehdi Hosseini-Mazinani, Gunna Christiansen, Jane L Ward, Dina Morshedi and Daniel E. Otzen

J. Biol. Chem. published online January 17, 2019

Access the most updated version of this article at doi: 10.1074/jbc.RA118.005723

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts
Oleuropein derivatives from olive fruit extracts reduce α-synuclein fibrillation and oligomer toxicity

Hossein Mohammad-Beigi, Farhang Aliakbari, Cagla Sahin, Charlotte Lomax, Ahmed Tawfike, Nicholas P. Schafer, Alireza Amiri-Nowdijeh, Hoda Eskandari, Ian Max Møller, Mehdi Hosseini-Mazinani, Gunna Christiansen, Jane L. Ward, Dina Morshedi, Daniel E. Otzen

Supplementary Figures S1-14 and Tables S1-3

Supplementary Figures

**Fig. S1.** The effect of different olive fruit extracts on αSN fibrillation. First screening: Selection of the best extracts by the effect of (A) 0.025 mg/ml extract and (B) 0.3 mg/ml extract on the end-point ThT fluorescence level at 1 mg/ml αSN.

**Fig. S2.** SDS-PAGE analysis of the supernatants of samples of 1 mg/ml αSN incubated for 24 h in the presence of 0-0.3 mg/ml of Koroneiki extract. Arrows highlight dimers (≈35 kDa) and oligomers (> 250 kDa).
Fig. S3. Oligomerization assay. (A) SEC profile of the supernatants from solutions of 1 mg/ml αSN incubated for 1 h at 37°C in the presence of different extracts. (B) Area under the peaks of small and large oligomers formed in the absence (Ctrl) and presence of 0.15 mg/ml of the best extracts.
**Fig. S4.** Disaggregation assay. SEC profile of the supernatants of preformed αSN fibrils incubated at 0.5 mg/ml overnight at 37°C in the absence (Ctrl) and presence of 0.15 mg/ml of the best extracts.
Fig. S5. Antioxidant activity and toxicity of the olive extracts. (A) Antioxidant activity of different olive fruit extracts at different concentrations (0.02, 0.04, 0.08, 0.12 mg/ml) measured by DPPH assay. (B) Viability of OLN-93 cells after 24 h incubation with the best olive extracts at different concentrations (0.025, 0.2, 0.5 mg/ml). (C) Oxidative stress in OLN-93 cells treated with olive extracts at different concentrations determined by DCFH-DA assay. (D) Free radical scavaging ability of the olive extracts measured in OLN-93 cells treated with 100 µM H₂O₂. (E) Viability of SH-SY5Y cells after 24 h incubation with 0-0.5 mg/ml of the best olive extracts.
Fig. S6. HPLC chromatograms of the 7 most efficient anti-aggregative olive extracts, recorded at 230 nm.

Fig. S7. Chromatogram of Koroneiki extract using HPLC. Fractions T1-26 are indicated. The different were identified by HPLC-MS.
Fig. S8. The effect of (A) 1 mg/ml and (B) 3 mg/ml of the Koroneiki extract fractions on fibrillation of 1 mg/ml $\alpha$SN. Maximum ThT fluorescence intensity normalized to control (absence of extract).
**Fig. S9.** The effect of Koroneiki extract fractions (3 mg/ml) on the kinetics of fibrillation of 1 mg/ml αSN monitored by ThT fluorescence.
Fig. S10. TEM images of 1 mg/ml αSN incubated alone (control) and in the presence of 3 mg/ml of Koroneiki extract fractions.
**Fig. S11.** SEC profiles of the supernatants of (A) samples of 1 mg/ml αSN incubated for 1 h at 37°C in an oligomerization assay and (B) 0.5 mg/ml preformed αSN fibrils preincubated overnight at 37°C with and without 3 mg/ml of Koroneiki extract fractions in a disaggregation assay.
**Fig. S12.** (A) Antioxidant activity of Koroneiki extract fractions (3 mg/ml) measured by DPPH assay. Viability of (B) OLN-93 and (C) SH-SY5Y cells after 24 h incubation with 1-3 mg/ml Koroneiki extract fractions.
Fig. S13. Total ion chromatograms of Koroneiki fractions
Fig. S13 (cont’d). Total ion chromatograms of Koroneiki fractions.
Fig. S14. Change in the level of compounds in the extracts of fruits picked at different maturation time (3, 4, 5, and 6 months after flowering) and their inhibitory effect on αSN fibrillation. HPLC chromatogram of the extracts (A, C, and E) and their effect on the maximum ThT fluorescence intensity (B, D, and F).
**Table S1.** Olive cultivars used in this study.

<table>
<thead>
<tr>
<th>Nr</th>
<th>Olive Cultivar</th>
<th>Abbreviation</th>
<th>Origin</th>
<th>Nr</th>
<th>Olive Cultivar</th>
<th>Abbreviation</th>
<th>Origin</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Koroneiki</td>
<td>-</td>
<td>Greece</td>
<td>9</td>
<td>Chenaran</td>
<td>T16</td>
<td>Iran</td>
</tr>
<tr>
<td>2</td>
<td>Arbequina</td>
<td>-</td>
<td>Spain</td>
<td>10</td>
<td>Khoshe</td>
<td>T17</td>
<td>Iran</td>
</tr>
<tr>
<td>3</td>
<td>Picual</td>
<td>-</td>
<td>Spain</td>
<td>11</td>
<td>Parseh</td>
<td>T18</td>
<td>Iran</td>
</tr>
<tr>
<td>4</td>
<td>Mari</td>
<td>-</td>
<td>Iran</td>
<td>12</td>
<td>Majnon</td>
<td>T20</td>
<td>Iran</td>
</tr>
<tr>
<td>5</td>
<td>Rowghani</td>
<td>-</td>
<td>Iran</td>
<td>13</td>
<td>Tak</td>
<td>T22</td>
<td>Iran</td>
</tr>
<tr>
<td>6</td>
<td>Zard</td>
<td>-</td>
<td>Iran</td>
<td>14</td>
<td>Zarin</td>
<td>T23</td>
<td>Iran</td>
</tr>
<tr>
<td>7</td>
<td>Yaghout</td>
<td>T10</td>
<td>Iran</td>
<td>15</td>
<td>Arghavan</td>
<td>T24</td>
<td>Iran</td>
</tr>
<tr>
<td>8</td>
<td>Gorgan</td>
<td>T15</td>
<td>Iran</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table S2. LC-MS data of fractions f5, 6, and 17-26 of Koroneiki extract obtained from HPLC separation

<table>
<thead>
<tr>
<th>Peak</th>
<th>Retention time (min)</th>
<th>m/z</th>
<th>Predicted ion formula</th>
<th>Delta (ppm)</th>
<th>MS-MS</th>
<th>(\lambda_{\text{max}})</th>
<th>Identity or Compound class</th>
<th>How identified</th>
<th>Previously observed in <em>Olea</em> species? (reference)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>7.63</td>
<td>153.0556</td>
<td>[C₈H₉O₃]⁻</td>
<td>0.94</td>
<td>123 (C₆H₄O₂)</td>
<td>281</td>
<td>Hydroxytyrosol</td>
<td>authentic standard</td>
<td>Yes (1)</td>
</tr>
<tr>
<td>2</td>
<td>8.67</td>
<td>151.0401</td>
<td>[C₈H₇O₃]⁻</td>
<td>1.49</td>
<td>-</td>
<td>280</td>
<td>4-Hydroxyphenylacetate</td>
<td>Accurate mass.</td>
<td>Yes (1)</td>
</tr>
<tr>
<td>3</td>
<td>11.46</td>
<td>315.1086</td>
<td>[C₁₄H₁₉O₈]⁻</td>
<td>1.29</td>
<td>153 (C₈H₉O₃)</td>
<td>278</td>
<td>Hydroxytyrosol glucoside</td>
<td>MSMS and literature data⁹</td>
<td>Yes (1)</td>
</tr>
<tr>
<td>4</td>
<td>12.33</td>
<td>245.1034</td>
<td>[C₁₁H₁₇O₆]⁻</td>
<td>1.39</td>
<td>-</td>
<td>-</td>
<td>Unknown</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>5</td>
<td>12.41</td>
<td>389.1090</td>
<td>[C₁₅H₂₇O₁₁]⁻</td>
<td>1.11</td>
<td>227 (C₁₅H₁₁O₆), 183 (C₉H₁₅O₃), 165 (C₈H₉O₃), 121 (C₆H₅O), 89 (C₃H₅O₃)</td>
<td>Oleoside</td>
<td>RT, MS, MSMS and literature data⁶</td>
<td>Yes (2)</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>13.25</td>
<td>407.1560</td>
<td>[C₁₇H₂₇O₁₁]⁻</td>
<td>1.21</td>
<td>389 (C₁₇H₂₅O₁₀), 377 (C₁₆H₂₃O₁₀), 357 (C₁₅H₂₁O₁₀), 313 (C₁₃H₁₉O₇), 183 (C₁₀H₁₇O₅), 151 (C₈H₁₅O₃), 113 (C₆H₉O₃), 101 (C₄H₅O₃), 89 (C₃H₅O₃)</td>
<td>Glucosyl acyclodihydroelenolic acid isomer I</td>
<td>Putative from MSMS.</td>
<td>Yes (3)</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>13.55</td>
<td>407.1560</td>
<td>[C₁₇H₂₇O₁₁]⁻</td>
<td>1.24</td>
<td>389 (C₁₇H₂₅O₁₀), 377 (C₁₆H₂₃O₁₀), 357 (C₁₅H₂₁O₁₀), 313 (C₁₃H₁₉O₇), 183 (C₁₀H₁₇O₅), 151 (C₈H₁₅O₃), 113 (C₆H₉O₃), 101 (C₄H₅O₃), 89 (C₃H₅O₃)</td>
<td>Glucosyl acyclodihydroelenolic acid isomer II</td>
<td>Putative from MSMS. Identical to Peak 6</td>
<td>Yes (3)</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>17.10</td>
<td>435.1506</td>
<td>[C₁₈H₂₇O₁₂]⁻</td>
<td>0.877</td>
<td>357 (C₁₈H₂₇O₁₀), 313 (C₁₆H₂₃O₈), 183 (C₁₅H₂₁O₆), 169 (C₁₃H₁₉O₄), 151 (C₈H₁₅O₂), 113 (C₆H₉O₂), 101 (C₄H₅O₂)</td>
<td>219</td>
<td>Formate adduct of Loganin(C₁₇H₂₅O₁₀)</td>
<td>RT, MS, MSMS and literature data⁶</td>
<td>Yes (2)</td>
</tr>
<tr>
<td>No.</td>
<td>RT (min)</td>
<td>m/z (s/p)</td>
<td>Molecule</td>
<td>Calculated M (Da)</td>
<td>Exact M (Da)</td>
<td>Intensity</td>
<td>Evidence</td>
<td>Authenticity</td>
<td>Comments</td>
</tr>
<tr>
<td>-----</td>
<td>----------</td>
<td>-----------</td>
<td>----------</td>
<td>------------------</td>
<td>-------------</td>
<td>----------</td>
<td>----------</td>
<td>-------------</td>
<td>----------</td>
</tr>
<tr>
<td>9</td>
<td>18.88</td>
<td>305.1038</td>
<td>[C_{16}H_{17}O_{6}]^-</td>
<td>1.82</td>
<td>153 (C_{6}H_{4}O_{3}), 151 (C_{6}H_{2}O_{2}), 123 (C_{7}H_{2}O_{3})</td>
<td>217</td>
<td>Conjugate of hydroxytyrosol and hydroxyphenyl acetate (ie 4-(hydroxyphenyl)ethyl 2-(4-hydroxyphenyl)acetate) OR conjugate of Vanillin and hydroxy tyrosol</td>
<td>Putative based on MS/MS fragmentati on</td>
<td>-</td>
</tr>
<tr>
<td>10</td>
<td>20.70</td>
<td>609.1514</td>
<td>[C_{27}H_{29}O_{16}]^-</td>
<td>1.17</td>
<td>300 (C_{15}H_{2}O_{2})</td>
<td>253, 354</td>
<td>Rutin</td>
<td>Authentic standard</td>
<td>Yes (2)</td>
</tr>
<tr>
<td>11</td>
<td>21.08</td>
<td>653.2030</td>
<td>[C_{30}H_{37}O_{16}]^-</td>
<td>1.30</td>
<td>621 (C_{28}H_{33}O_{15}), 459 (C_{28}H_{32}O_{12}), 179 (C_{9}H_{7}O_{4}), 161 (C_{9}H_{5}O_{3}), 151 (C_{8}H_{7}O_{3})</td>
<td>218</td>
<td>Methoxyverbascoside</td>
<td>RT, MS, MSMS and literature data</td>
<td>Yes (2)</td>
</tr>
<tr>
<td>12</td>
<td>21.27</td>
<td>447.0934</td>
<td>[C_{21}H_{19}O_{11}]^-</td>
<td>1.18</td>
<td>285 (C_{15}H_{6}O_{6})</td>
<td>346</td>
<td>Luteolin-7-glucoside</td>
<td>Authentic standard</td>
<td>Yes (2)</td>
</tr>
<tr>
<td>13</td>
<td>21.35</td>
<td>453.2337</td>
<td>[C_{20}H_{37}O_{11}]^-</td>
<td>0.63</td>
<td>321 (C_{15}H_{2}O_{10}), 233 (C_{15}H_{3}O_{9}), 191 (C_{15}H_{1}O_{8}), 161 (C_{9}H_{2}O_{3}), 113 (C_{9}H_{4}O_{2}), 101 (C_{8}H_{6}O_{1})</td>
<td>218</td>
<td>Unknown</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>14</td>
<td>21.46</td>
<td>241.0719</td>
<td>[C_{15}H_{13}O_{6}]^-</td>
<td>0.169</td>
<td>139 (C_{6}H_{4}O_{2})</td>
<td>219,328</td>
<td>Unknown</td>
<td>RT, MS, MSMS and literature data</td>
<td>Yes (1)</td>
</tr>
<tr>
<td>15</td>
<td>21.49</td>
<td>623.2022</td>
<td>[C_{22}H_{39}O_{20}]^-</td>
<td>-0.71</td>
<td>461 (C_{12}H_{1}O_{15}), 179 (C_{9}H_{4}O_{2}), 161 (C_{9}H_{4}O_{6})</td>
<td>330</td>
<td>Verbascoside</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>16</td>
<td>21.50</td>
<td>505.2626</td>
<td>[C_{2d}H_{4}O_{11}]^-</td>
<td>251 (C_{9}H_{15}O_{8}), 191 (C_{9}H_{1}O_{8}), 149 (C_{9}H_{4}O_{2}), 131 (C_{9}H_{4}O_{2}), 101 (C_{9}H_{4}O_{2}), 89 (C_{8}H_{6}O_{1})</td>
<td>Unknown diglycoside</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>21.86</td>
<td>505.2625</td>
<td>[C_{2d}H_{4}O_{11}]^-</td>
<td>373 (C_{10}H_{15}O_{7}), 233 (C_{9}H_{15}O_{7}), 161 (C_{8}H_{4}O_{8}), 89 (C_{8}H_{6}O_{2})</td>
<td>Unknown diglycoside</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>21.89</td>
<td>465.2323</td>
<td>n.d.</td>
<td>333 (C_{10}H_{15}O_{7}), 233 (C_{9}H_{15}O_{7}), 161 (C_{8}H_{4}O_{8}), 113 (C_{9}H_{4}O_{2}), 101 (C_{9}H_{4}O_{2})</td>
<td>218</td>
<td>Unknown</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>RT</td>
<td>MS</td>
<td>MSMS</td>
<td>M/z</td>
<td>Compendial Name</td>
<td>Identification</td>
<td>Refs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>-------</td>
<td>-------</td>
<td>------</td>
<td>---------</td>
<td>-----------------------------------------------------</td>
<td>---------------</td>
<td>------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>22.08</td>
<td>465.2332</td>
<td>n.d.</td>
<td>333 (C_{16}H_{29}O_{7}), 233 (C_{6}H_{13}O_{7}), 161 (C_{4}H_{5}O_{3}), 113 (C_{4}H_{5}O_{3}), 101 (C_{4}H_{5}O_{3}), 89 (C_{3}H_{5}O_{3})</td>
<td>Unknown, isomer of 18</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>22.32</td>
<td>543.2047</td>
<td>[C_{25}H_{35}O_{13}]$^-$</td>
<td>-2.55</td>
<td>377 (C_{16}H_{25}O_{10}), 357 (C_{16}H_{21}O_{6}), 313 (C_{13}H_{15}O_{7}), 197 (C_{10}H_{12}O_{4}), 101 (C_{11}H_{15}O_{6}), 101 (C_{6}H_{9}O_{5})</td>
<td>Dihydrooleuropein</td>
<td>RT, MS, MSMS. And ref $^a$</td>
<td>Yes (4)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>623.2041</td>
<td>[C_{25}H_{35}O_{20}]$^-$</td>
<td>1.21</td>
<td>461 (C_{16}H_{29}O_{15}), 179 (C_{6}H_{9}O_{5}), 161 (C_{6}H_{9}O_{5})</td>
<td>Verbascoside isomer</td>
<td>Yes (2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>22.73</td>
<td>701.2235</td>
<td>[C_{31}H_{41}O_{18}]$^-$</td>
<td>-5.92</td>
<td>377 (C_{19}H_{21}O_{8}), 307 (C_{15}H_{15}O_{7}), 275 (C_{15}H_{15}O_{7}), 221 (C_{15}H_{13}O_{7}), 179 (C_{15}H_{13}O_{7}), 149 (C_{15}H_{13}O_{7}), 149 (C_{15}H_{13}O_{7}), 101 (C_{6}H_{11}O_{6})</td>
<td>Oleuropein glycoside isomer</td>
<td>RT, MS, MSMS. And ref $^b$</td>
<td>Yes (2)</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>22.99</td>
<td>701.2213</td>
<td>[C_{31}H_{41}O_{18}]$^-$</td>
<td>-7.44</td>
<td>377 (C_{19}H_{21}O_{8}), 307 (C_{15}H_{15}O_{7}), 275 (C_{15}H_{15}O_{7}), 221 (C_{15}H_{13}O_{7}), 179 (C_{15}H_{13}O_{7}), 149 (C_{15}H_{13}O_{7}), 149 (C_{15}H_{13}O_{7}), 101 (C_{6}H_{11}O_{6})</td>
<td>Oleuropein glycoside isomer</td>
<td>RT, MS, MSMS. And ref $^b$</td>
<td>Yes (2)</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>23.01</td>
<td>447.0924</td>
<td>[C_{21}H_{19}O_{11}]$^-$</td>
<td>-0.91</td>
<td>285 (C_{15}H_{9}O_{6})</td>
<td>Luteolin glycoside isomer</td>
<td>By MSMS</td>
<td>Yes (2)</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>23.22</td>
<td>467.2479</td>
<td>[C_{21}H_{39}O_{11}]$^-$</td>
<td>-0.81</td>
<td>335 (C_{16}H_{31}O_{7}), 233 (C_{6}H_{11}O_{4}), 161 (C_{6}H_{11}O_{4}), 101 (C_{6}H_{11}O_{4}), 89 (C_{6}H_{11}O_{4})</td>
<td>Terpene diglycoside (Putative)</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>23.32</td>
<td>551.1416</td>
<td>[C_{21}H_{25}O_{14}]$^-$</td>
<td>1.94</td>
<td>161 (C_{6}H_{11}O_{4})</td>
<td>Cinnamoyl hydroxyloganin (PUTATIVE)</td>
<td>Putative;</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>701.2344</td>
<td>[C_{21}H_{39}O_{11}]$^-$</td>
<td>5.70</td>
<td>539, 371 (C_{16}H_{29}O_{10}), 307 (C_{15}H_{15}O_{7}), 275 (C_{15}H_{15}O_{7}), 223 (C_{15}H_{15}O_{7})</td>
<td>Oleuropein-glucoside or Aleuricine A/B</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>23.43</td>
<td>381.1555</td>
<td>[C\textsubscript{10}H\textsubscript{25}O\textsubscript{5}]</td>
<td>1.11</td>
<td>231 (C\textsubscript{9}H\textsubscript{13}O\textsubscript{6}), 201 (C\textsubscript{8}H\textsubscript{13}O\textsubscript{5}), 183 (C\textsubscript{9}H\textsubscript{11}O\textsubscript{4}), 151 (C\textsubscript{9}H\textsubscript{11}O\textsubscript{2}), 139 (C\textsubscript{9}H\textsubscript{11}O\textsubscript{3}), 119 (C\textsubscript{6}H\textsubscript{11}O\textsubscript{6}), 101 (C\textsubscript{8}H\textsubscript{5}O\textsubscript{3})</td>
<td>HT-ACDE. (Hydroxytyrosylacyldihydro -elenolate)</td>
<td>RT, MS, MSMS.</td>
<td>Yes (5)</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>23.54</td>
<td>573.2135</td>
<td>n.d.</td>
<td>3.21</td>
<td>345 (C\textsubscript{13}H\textsubscript{21}O\textsubscript{8}), 225 (C\textsubscript{12}H\textsubscript{17}O\textsubscript{8}), 209 (C\textsubscript{10}H\textsubscript{15}O\textsubscript{8}), 183 (C\textsubscript{9}H\textsubscript{11}O\textsubscript{4}), 165 (C\textsubscript{8}H\textsubscript{11}O\textsubscript{2}), 141 (C\textsubscript{7}H\textsubscript{10}O\textsubscript{2}), 121 (C\textsubscript{6}H\textsubscript{11}O\textsubscript{2})</td>
<td>219</td>
<td>Unknown</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>28</td>
<td>24.00</td>
<td>539.1771</td>
<td>[C\textsubscript{21}H\textsubscript{31}O\textsubscript{13}]</td>
<td>1.12</td>
<td>403 (C\textsubscript{13}H\textsubscript{23}O\textsubscript{14}), 222 (C\textsubscript{11}H\textsubscript{13}O\textsubscript{2}), 179 (C\textsubscript{10}H\textsubscript{15}O\textsubscript{6}), 119 (C\textsubscript{9}H\textsubscript{13}O\textsubscript{4}), 113 (C\textsubscript{8}H\textsubscript{13}O\textsubscript{2}), 101 (C\textsubscript{6}H\textsubscript{12}O\textsubscript{2}), 95 (C\textsubscript{6}H\textsubscript{12}O\textsubscript{3})</td>
<td>346</td>
<td>Oleurosido isomer</td>
<td>MS, MSMS</td>
<td>-</td>
</tr>
<tr>
<td>29</td>
<td>24.10</td>
<td>549.2870</td>
<td>n.d</td>
<td>0.96</td>
<td>307 (C\textsubscript{13}H\textsubscript{15}O\textsubscript{7}), 275 (C\textsubscript{14}H\textsubscript{17}O\textsubscript{6}), 149 (C\textsubscript{13}H\textsubscript{15}O\textsubscript{5}), 139 (C\textsubscript{12}H\textsubscript{15}O\textsubscript{3}), 127 (C\textsubscript{11}H\textsubscript{15}O\textsubscript{2}), 111 (C\textsubscript{9}H\textsubscript{13}O\textsubscript{2}), 111 (C\textsubscript{8}H\textsubscript{13}O\textsubscript{2}), 101 (C\textsubscript{6}H\textsubscript{12}O\textsubscript{2}), 95 (C\textsubscript{6}H\textsubscript{12}O\textsubscript{3})</td>
<td>219</td>
<td>Unknown</td>
<td>Oleurope aglycone isomer</td>
<td>RT, MS, MSMS. And ref\textsuperscript{b}</td>
</tr>
<tr>
<td>30</td>
<td>24.29</td>
<td>569.1924</td>
<td>[C\textsubscript{25}H\textsubscript{33}O\textsubscript{14}]</td>
<td>-4.11</td>
<td>537 (C\textsubscript{23}H\textsubscript{32}O\textsubscript{15}), 403 (C\textsubscript{17}H\textsubscript{27}O\textsubscript{11}), 371 (C\textsubscript{16}H\textsubscript{29}O\textsubscript{10}), 305 (C\textsubscript{13}H\textsubscript{13}O\textsubscript{7}), 223 (C\textsubscript{11}H\textsubscript{11}O\textsubscript{4}), 151 (C\textsubscript{9}H\textsubscript{11}O\textsubscript{2})</td>
<td>Methoxyoleurope</td>
<td>RT, MS, MSMS. And ref\textsuperscript{b}</td>
<td>Yes (2)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>527.2092</td>
<td>[C\textsubscript{25}H\textsubscript{33}O\textsubscript{12}]</td>
<td>4.72</td>
<td>377 (C\textsubscript{16}H\textsubscript{27}O\textsubscript{10}), 313 (C\textsubscript{13}H\textsubscript{13}O\textsubscript{7}), 101 (C\textsubscript{9}H\textsubscript{11}O\textsubscript{2})</td>
<td>Coumaroyl bearing derivative</td>
<td>MSMS</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>31</td>
<td>24.61</td>
<td>539.1745</td>
<td>[C$<em>{25}$H$</em>{31}$O$_{13}$]$^-$</td>
<td>-1.44</td>
<td>403 (C$<em>{13}$H$</em>{25}$O$<em>{14}$), 371 (C$</em>{16}$H$<em>{19}$O$</em>{16}$), 307 (C$<em>{18}$H$</em>{15}$O$<em>{12}$), 275 (C$</em>{13}$H$<em>{15}$O$</em>{6}$), 223 (C$<em>{11}$H$</em>{11}$O$<em>{5}$), 179 (C$</em>{9}$H$<em>{11}$O$</em>{4}$), 149 (C$<em>{8}$H$</em>{11}$O$<em>{3}$) 119 (C$</em>{6}$H$<em>{11}$O$</em>{2}$), 101 (C$<em>{4}$H$</em>{5}$O$<em>{3}$), 95 (C$</em>{3}$H$_{7}$O)</td>
<td>222, 282</td>
<td>Oleuropein aglycone isomer</td>
<td>RT, MS, MSMS. And ref$^b$</td>
<td>Yes (2)</td>
</tr>
<tr>
<td>32</td>
<td>24.90</td>
<td>535.1430</td>
<td>[C$<em>{25}$H$</em>{31}$O$_{13}$]$^-$</td>
<td>-1.61</td>
<td>389 (C$<em>{14}$H$</em>{21}$O$<em>{11}$), 345 (C$</em>{16}$H$<em>{21}$O$</em>{10}$), 307 (C$<em>{16}$H$</em>{15}$O$<em>{5}$), 265 (C$</em>{13}$H$<em>{13}$O$</em>{6}$), 235 (C$<em>{12}$H$</em>{12}$O$<em>{5}$), 205 (C$</em>{11}$H$<em>{11}$O$</em>{4}$), 163 (C$<em>{9}$H$</em>{11}$O$<em>{3}$) 145 (C$</em>{8}$H$<em>{11}$O$</em>{2}$), 121 (C$<em>{6}$H$</em>{5}$O)</td>
<td>219, 312</td>
<td>6'-(E)-p-coumaroyl-secologanoside</td>
<td>MS, MSMS</td>
<td>Yes (4)</td>
</tr>
<tr>
<td>33</td>
<td>25.16</td>
<td>539.1730</td>
<td>[C$<em>{25}$H$</em>{31}$O$_{13}$]$^-$</td>
<td>1.91</td>
<td>403 (C$<em>{13}$H$</em>{25}$O$<em>{14}$), 327 (C$</em>{16}$H$<em>{15}$O$</em>{6}$), 307 (C$<em>{18}$H$</em>{15}$O$<em>{7}$), 275 (C$</em>{13}$H$<em>{15}$O$</em>{5}$), 223 (C$<em>{11}$H$</em>{11}$O$<em>{5}$), 197 (C$</em>{10}$H$<em>{13}$O$</em>{4}$), 165 (C$<em>{9}$H$</em>{11}$O$<em>{3}$), 149 (C$</em>{8}$H$<em>{11}$O$</em>{2}$) 139 (C$<em>{7}$H$</em>{11}$O$<em>{2}$), 119 (C$</em>{6}$H$<em>{11}$O$</em>{2}$), 101 (C$<em>{3}$H$</em>{7}$O)</td>
<td>219</td>
<td>Oleuropein Isomer</td>
<td>RT, MS, MSMS. And ref$^b$</td>
<td>Yes (2)</td>
</tr>
<tr>
<td>34</td>
<td>25.35</td>
<td>565.1511</td>
<td>[C$<em>{29}$H$</em>{29}$O$_{14}$]$^-$</td>
<td>-4.04</td>
<td>345 (C$<em>{15}$H$</em>{21}$O$<em>{3}$), 295 (C$</em>{14}$H$<em>{15}$O$</em>{5}$), 235</td>
<td>220, 327</td>
<td>Unknown</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>35</td>
<td>25.62</td>
<td>539.1793</td>
<td>([C_{15}H_31O_{13}]^-)</td>
<td>3.35</td>
<td>403 (C₁₂H₁₅O₁₄), 371 (C₁₆H₁₉O₁₀), 327 (C₁₃H₁₅O₉), 307 (C₁₃H₁₅O₇), 275 (C₁₃H₁₅O₅), 223 (C₁₁H₁₁O₈), 197 (C₁₀H₁₃O₄), 165 (C₈H₉O₃), 149 (C₈H₉O₂), 139 (C₇H₇O₃), 119 (C₆H₅O₃), 101 (C₅H₅O₂), 95 (C₅H₅O)</td>
<td>Oleuros As Isomer</td>
<td>MS, MS-MS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>36</td>
<td>25.77</td>
<td>543.2459</td>
<td>([C_{15}H_39O_{12}]^-)</td>
<td>2.61</td>
<td>375 (C₁₆H₂₃O₁₀), 357 (C₁₆H₂₃O₉), 227 (C₁₃H₁₅O₄), 213 (C₁₀H₁₃O₃), 199 (C₁₁H₁₉O₃), 185 (C₁₀H₁₃O₂), 169 (C₈H₉O₃), 151 (C₈H₉O₂), 125 (C₇H₇O₃), 113 (C₆H₅O₂), 95 (C₅H₅O₂), 87 (C₅H₅O)</td>
<td>Dihydro oleuropein</td>
<td>RT, MS, MS-MS</td>
<td>Yes (2)</td>
<td></td>
</tr>
<tr>
<td>37</td>
<td>25.99</td>
<td>535.1479</td>
<td>([C_{20}H_{27}O_{13}]^-)</td>
<td>3.33</td>
<td>389 (C₁₉H₂₁O₁₁), 345 (C₁₅H₁₅O₇), 307 (C₁₃H₁₅O₇), 265 (C₁₃H₁₅O₅), 235 (C₁₂H₁₁O₄), 205 (C₁₁H₉O₄), 163 (C₉H₇O₃), 145 (C₈H₇O₂), 121 (C₆H₅O)</td>
<td>Coumaroyl-secologanoside isomer</td>
<td>MS, MS-MS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>38</td>
<td>26.30</td>
<td>377.1243</td>
<td>([C_{10}H_{21}O_{8}]^-)</td>
<td>0.29</td>
<td>307 (C₁₀H₁₅O₇), 275 (C₁₀H₁₅O₆), 171 (C₉H₇O₃), 149 (C₈H₇O₂), 139 (C₇H₇O₂), 127 (C₆H₅O₂), 113 (C₅H₅O₂)</td>
<td>Isomer of oleuropein aglycone</td>
<td>MSMS</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>39</td>
<td>26.60</td>
<td>523.1780</td>
<td>[C_{26}H_{31}O_{12}]^+</td>
<td>3.12</td>
<td>361 (C_{18}H_{21}O_{7}), 291 (C_{16}H_{15}O_{6}), 259 (C_{15}H_{13}O_{4}), 101 (C_{4}H_{5}O_{3})</td>
<td>220, 276</td>
<td>Ligstroside (or isomer)</td>
<td>MSMS</td>
<td>Yes (6)</td>
</tr>
<tr>
<td>40</td>
<td>27.00</td>
<td>555.2100</td>
<td>[C_{26}H_{35}O_{13}]^+</td>
<td>2.74</td>
<td>511 (C_{23}H_{33}O_{7}), 345 (C_{18}H_{21}O_{6}), 327 (C_{13}H_{19}O_{5}), 225 (C_{12}H_{17}O_{4}), 197 (C_{11}H_{16}O_{3}), 183 (C_{10}H_{15}O_{3}), 165 (C_{9}H_{14}O_{2}), 155 (C_{8}H_{9}O_{2}), 139 (C_{7}H_{9}O_{2}), 121 (C_{6}H_{2}O)</td>
<td>220</td>
<td>Hydroxyoleuroside</td>
<td>RT, MS, MSMS and ref^{b}</td>
<td>Yes (2)</td>
</tr>
<tr>
<td>41</td>
<td>27.15</td>
<td>493.1330</td>
<td>[C_{23}H_{25}O_{12}]^+</td>
<td>-1.04</td>
<td>327 (C_{18}H_{19}O_{5}), 209 (C_{10}H_{9}O_{2}), 183 (C_{8}H_{11}O_{2}), 165 (C_{7}H_{9}O_{2}), 135 (C_{6}H_{9}O_{2}), 121 (C_{5}H_{5}O_{2})</td>
<td>220</td>
<td>Unknown</td>
<td></td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>27.46</td>
<td>555.2040</td>
<td>[C_{26}H_{35}O_{13}]^+</td>
<td>-3.20</td>
<td>345 (C_{23}H_{33}O_{7}), 327 (C_{18}H_{21}O_{6}), 225 (C_{13}H_{19}O_{5}), 197 (C_{12}H_{17}O_{4}), 183 (C_{11}H_{16}O_{3}), 165 (C_{10}H_{15}O_{3}), 155 (C_{9}H_{14}O_{2}), 139 (C_{8}H_{9}O_{2}), 121 (C_{6}H_{2}O)</td>
<td>220</td>
<td>Hydroxyoleuroside isomer</td>
<td>MS, MSMS</td>
<td></td>
</tr>
<tr>
<td>43</td>
<td>27.70</td>
<td>377.1243</td>
<td>[C_{10}H_{2}O_{3}]^+</td>
<td>0.21</td>
<td>307 (C_{13}H_{15}O_{2}), 275 (C_{14}H_{11}O_{6}), 191 (C_{10}H_{9}O_{2}), 171 (C_{8}H_{11}O_{4}), 149 (C_{6}H_{9}O_{2}), 139 (C_{5}H_{9}O_{2}), 127 (C_{4}H_{7}O_{2}), 111 (C_{3}H_{5}O_{2}), 101 (C_{2}H_{3}O_{2}), 95 (C_{4}H_{3}O_{2})</td>
<td>220</td>
<td>Isomer of oleuropein aglycone</td>
<td>RT, MS, MSMS and ref^{b}</td>
<td>Yes (2)</td>
</tr>
<tr>
<td>44</td>
<td>28.10</td>
<td>461.2013</td>
<td>[C_{21}H_{33}O_{11}]^+</td>
<td>-0.43</td>
<td>167 (C_{10}H_{15}O_{2})</td>
<td>Unknown</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>RT</td>
<td>MS</td>
<td>MSMS data</td>
<td>Putative from MSMS data</td>
<td>MSMS data</td>
<td>Yes (4)</td>
<td>Hydroxyoleuropein aglycone</td>
<td>Putative from MSMS data</td>
<td>Yes (4)</td>
<td>MSMS data</td>
</tr>
<tr>
<td>------</td>
<td>-----</td>
<td>-----------</td>
<td>--------------------------</td>
<td>-----------</td>
<td>---------</td>
<td>--------------------------------</td>
<td>--------------------------</td>
<td>---------</td>
<td>-----------</td>
</tr>
<tr>
<td>28.14</td>
<td>393.1191</td>
<td>[C\textsubscript{19}H\textsubscript{21}O\textsubscript{9}]\textsuperscript{-}</td>
<td>1.05</td>
<td>317 (C\textsubscript{17}H\textsubscript{17}O\textsubscript{3}), 181 (C\textsubscript{9}H\textsubscript{9}O\textsubscript{4}), 137 (C\textsubscript{6}H\textsubscript{3}O\textsubscript{5})</td>
<td>220</td>
<td>Hydroxyoleuropein aglycone</td>
<td>Putative from MSMS data</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>28.29</td>
<td>557.2192</td>
<td>[C\textsubscript{26}H\textsubscript{37}O\textsubscript{13}]\textsuperscript{-}</td>
<td>-3.68</td>
<td>345 (C\textsubscript{15}H\textsubscript{21}O\textsubscript{4}), 227 (C\textsubscript{12}H\textsubscript{16}O\textsubscript{2}), 199 (C\textsubscript{11}H\textsubscript{18}O\textsubscript{2}), 185 (C\textsubscript{10}H\textsubscript{21}O\textsubscript{3}), 165 (C\textsubscript{9}H\textsubscript{9}O\textsubscript{4}), 139 (C\textsubscript{6}H\textsubscript{3}O\textsubscript{5}), 121 (C\textsubscript{3}H\textsubscript{3}O\textsubscript{4})</td>
<td>220</td>
<td>6'-O-[(2E)-2,6-dimethyl-8-hydroxy-2-octenoyl]secologanoside</td>
<td>MSMS data</td>
<td>Yes (4)</td>
<td>MSMS data</td>
</tr>
<tr>
<td>29.95</td>
<td>545.2563</td>
<td>n.d.</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Unknown</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>30.08</td>
<td>377.1242</td>
<td>[C\textsubscript{10}H\textsubscript{21}O\textsubscript{8}]\textsuperscript{-}</td>
<td>1.10</td>
<td>307 (C\textsubscript{15}H\textsubscript{21}O\textsubscript{7}), 275 (C\textsubscript{14}H\textsubscript{21}O\textsubscript{6}), 191 (C\textsubscript{10}H\textsubscript{17}O\textsubscript{4}), 171 (C\textsubscript{6}H\textsubscript{3}O\textsubscript{4}), 149 (C\textsubscript{8}H\textsubscript{9}O\textsubscript{3}), 139 (C\textsubscript{6}H\textsubscript{3}O\textsubscript{4}), 127 (C\textsubscript{9}H\textsubscript{9}O\textsubscript{3}), 111 (C\textsubscript{6}H\textsubscript{3}O\textsubscript{4}), 101 (C\textsubscript{6}H\textsubscript{3}O\textsubscript{4}), 95 (C\textsubscript{6}H\textsubscript{3}O)</td>
<td>220</td>
<td>Oleuropein aglycone</td>
<td>MSMS data</td>
<td>Yes (4)</td>
<td>MSMS data</td>
</tr>
<tr>
<td>31.19</td>
<td>377.1243</td>
<td>[C\textsubscript{10}H\textsubscript{21}O\textsubscript{8}]\textsuperscript{-}</td>
<td>0.24</td>
<td>307 (C\textsubscript{15}H\textsubscript{21}O\textsubscript{7}), 275 (C\textsubscript{14}H\textsubscript{21}O\textsubscript{6}), 191 (C\textsubscript{10}H\textsubscript{17}O\textsubscript{4}), 171 (C\textsubscript{6}H\textsubscript{3}O\textsubscript{4}), 149 (C\textsubscript{8}H\textsubscript{9}O\textsubscript{3}), 139 (C\textsubscript{6}H\textsubscript{3}O\textsubscript{4}), 127 (C\textsubscript{9}H\textsubscript{9}O\textsubscript{3}), 111 (C\textsubscript{6}H\textsubscript{3}O\textsubscript{4}), 101 (C\textsubscript{6}H\textsubscript{3}O\textsubscript{4}), 95 (C\textsubscript{6}H\textsubscript{3}O)</td>
<td>220</td>
<td>Isomer of oleuropein aglycone</td>
<td>MSMS data</td>
<td>Yes (4)</td>
<td>MSMS data</td>
</tr>
<tr>
<td>32.21</td>
<td>943.3442</td>
<td>[C\textsubscript{43}H\textsubscript{59}O\textsubscript{23}]\textsuperscript{-}</td>
<td>0.05</td>
<td>513 (C\textsubscript{35}H\textsubscript{35}O\textsubscript{4}), 345 (C\textsubscript{15}H\textsubscript{21}O\textsubscript{4}), 227 (C\textsubscript{12}H\textsubscript{16}O\textsubscript{2}), 209 (C\textsubscript{10}H\textsubscript{21}O\textsubscript{3}), 185 (C\textsubscript{10}H\textsubscript{17}O\textsubscript{3}), 165 (C\textsubscript{9}H\textsubscript{9}O\textsubscript{4}), 149 (C\textsubscript{6}H\textsubscript{3}O\textsubscript{4}), 139 (C\textsubscript{6}H\textsubscript{3}O\textsubscript{4}), 121 (C\textsubscript{6}H\textsubscript{3}O\textsubscript{4}), 101 (C\textsubscript{6}H\textsubscript{3}O\textsubscript{4})</td>
<td>222</td>
<td>Unknown</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
Table S3. Major compounds identified in fractions from the Koroneiki extract

<table>
<thead>
<tr>
<th>Nr</th>
<th>Fraction</th>
<th>Major compounds</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5</td>
<td>Hydroxytyrosol, Hydroxytyrosol glucoside, and Oleoside</td>
</tr>
<tr>
<td>2</td>
<td>6</td>
<td>Acyclodihydroelenolic acid glucoside isomer, Loganin</td>
</tr>
<tr>
<td>3</td>
<td>17</td>
<td>Rutin</td>
</tr>
<tr>
<td>4</td>
<td>18</td>
<td>Verbacoside</td>
</tr>
<tr>
<td>5</td>
<td>19</td>
<td>Dihydro oleuropein</td>
</tr>
<tr>
<td>6</td>
<td>20</td>
<td>Oleuropein glucoside</td>
</tr>
<tr>
<td>7</td>
<td>21</td>
<td>Oleuropein</td>
</tr>
<tr>
<td>8</td>
<td>22</td>
<td>Oleuropein and Coumaroyl-sceloganoside</td>
</tr>
<tr>
<td>9</td>
<td>23</td>
<td>Dimethyl Hydroxyoctenoyl-sceloganoside</td>
</tr>
<tr>
<td>10</td>
<td>24</td>
<td>Hydroxyoleuropein aglycone, Oleuropein aglycone</td>
</tr>
<tr>
<td>11</td>
<td>25</td>
<td>Oleuropein aglycone</td>
</tr>
<tr>
<td>12</td>
<td>26</td>
<td>Oleuropein aglycone</td>
</tr>
</tbody>
</table>

References